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1
CHAPTER 1: INTRODUCTION OF PROTON AND PHOTON
RADIOTHERAPY WITH MOTION MANAGEMENT
1.1

General Overview of Radiotherapy
Radiation was first discovered by Wilhelm Conrad Roentgen at the end of

the 19th century. While performing experiments using positive and negative
charged electrodes, he noticed a green fluorescence color upon the application
of high voltage. Intrigued by such light and unable to identify it, Wilhelm called
them unknown rays or “X”-rays. Furthermore, in late 1895, he discovered that
such unknown “rays” were capable of penetrating through some objects, but not
the other. This phenomenon was observed when he first photographed his wife
Bertha’s hand. It was clear from the photograph that denser materials, like
Bertha’s ring, created a much darker image, resulting in less penetration of the
unknown “X”-rays.
Just after the discovery of the unknown “X”-rays, Becquerel, a French
scientist, noticed that storing a sample of uranium under a photographic plate, in
a cloudy day, the plate still appeared to have been exposed to light (Reed & Pa,
2011). Like Roentgen, Becquerel was also able to deduce that uranium was
emitting natural radiation. This remarkable work was further researched by
Mme. Curie who was recognized as a Nobel Prize winner, together with
Becquerel in 1903.
Although the above discoveries drastically changed the field for decades
thereafter, the initial consequences on human health were still unknown despite
the initial theorization by Mme. Curie that radiation could indeed become

2
dangerous by indicating in her Nobel Prize notes that: “…if one leaves a small
glass ampulla with several centigrams of radium salt in one’s pocket for a few
hours, one will feel absolutely nothing. But the 15 days afterwards redness will
appear on the epidermis…”. Although, her statement was not backed up by
broad scientific data or massive trials like those performed today, it was certainly
an observation that Mme. and her husband Pierre Curie noticed accidentally
(Curie, 1967). Consequently, radiation was often used as a tool by the general
public to create “cool toys” for the kids, measure show sizes, and design glowing
watches for the adults. As further research was performed, the scientific
community began to understand more about the unknown “rays” and the
implications to human health since the broad and uncontrolled use of radiation
led health implications (Reed & Pa, 2011).
Today, we know more about radiation (“X”-ray) itself and its interaction with
matter. We define radiation as emission and propagation of energy in space or
medium.

Most textbooks will define radiation as particle or wave. Particle

radiation is propagation of energy by traveling corpuscles that have a defined
rest mass and within limits have a defined momentum and defined position at
any instant” (Faiz Khan, Structure of Matter, 2003). Consequently, the wave
model, also known as the electromagnetic model, is described as the oscillating
electric and magnetic field. An electromagnetic wave can be represented by the
spatial variations in the intensities of an electric field and the magnetic field, the
fields being at right angles to each other at any given instant (Faiz Khan,
Structure of Matter, 2003).
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Furthermore, electromagnetic radiation can be divided into several modes
like: light waves, heat waves, radio waves, microwaves, ultraviolet rays, X-rays
and Γ -rays (in order of increasing energy). All of these modes can be further
explained by the following equation:
=ℏ
Where E is the energy carried by the photon, ℏ is the Planks constant and

(1)
is

the frequency. With frequency being defined as:
ν=
where c is the speed of light and

(2)

is the wavelength. It is obvious from

equations (1) and (2) that the shorter the wavelength the higher the energy. As a
result, the X- and Γ-ray of the spectrum mentioned above would exhibit a much
higher energy than that of visible light.
There are two different ways of producing X-rays. The first method is
bremsstrahlung and the second is characteristic. Bremsstrahlung X-ray comes
from the German word “to break”. In this method, the interaction of high energy
electrons to the Coulomb field of a nucleus deaccelerates the incoming electron
leading to loss of energy that is emitted as X-ray. The mechanics of this method
are well known and widely used in both diagnostic and therapy setting. The
second method, characteristic X-ray, constitutes of an incoming electron
interacting with an orbital electron of an atom, leading to a vacant spot, which is
known as an ionized atom. When this vacancy is created, another electron from
an outer orbital will drop down and fill the vacancy, releasing characteristic
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energy in the process. This characteristic X-ray is ‘characteristic’ of the binding
energy difference of the orbital shells involved.
The main difference between X- and Γ- rays is their origin, but their
interaction with medium is described by three different techniques:


Photoelectric effect: this phenomenon occurs when the incoming photon
is completely absorbed by an atom in the medium, resulting in one of the
orbital electrons to be ejected. Such interaction will occur with a tightly
bound electron, like those in the inner most shells. Essentially, all of the
energy from the incoming photon ( = ℎ ) is transferred to the ejected
electron. The resulting energy of the ejected electron is T = hν −
where hυ the energy of the incoming photon is and

is the binding

energy of the bound electron. The probability of this interaction to occur
depends on the photon energy and the atomic number of the absorbing
material (medium). This relation is often denoted as:

where Z is the

atomic number of the medium and E is the energy of the incoming
photon. Therefore, photoelectric interaction will be more prominent for
high Z and low E.


Compton effect: this phenomenon occurs when the incoming photon
interacts with a free bound atomic electron in the medium, resulting in the
scatter of the electron and photon. There are special cases that one can
apply, together with the laws of conservation of energy and momentum,
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to determine the final energy of the ejected electron and photon. The
energy of the ejected electron is denoted as:

=ℎ

ℎ ′

−
1+

ℎ

(3)

(1 −

)

And the energy of the ejected photon is:

ℎ

ℎ

=
1+

Where ℎ

ℎ

(1 −

(4)
)

is the energy of the incoming photon, ℎ ′ is the energy of the

ejected photon, T is the energy of ejected electron,

is rest energy of

the electron and φ is the angle of scattered photon. The probability of a
photon going through a Compton interaction will depend on the electron
density, which is the number of electrons per unit mass. This is described
in literature as

/ . Therefore, unlike photoelectric, Compton interaction

is independent of Z and proportional to Z/A. The probability of Compton
decreases with increasing photon energy.


Pair production: this phenomenon occurs when an incoming photon is
completely absorbed in the Coulomb field of an atomic nucleus to create
an electron and positron pair. The average energy received by the
electron and positron is:

=
Where ℎ

ℎ

− 1.022
2

(5)

is the energy of the incoming photon and 1.022 MeV is the

rest energy of the electron and positron. The probability of this interaction
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to occur increases with increase in photon energy and increases with
atomic number by approximately Z2.
Until now, we’ve discussed the production of x-ray (photon), their three main
interactions with matter, and the probability of the interaction to occur. However,
as described in literature (Kogel, 2009), it is the charged particles that would
eventually create the most biological effects that clinicians aim to deliver to a
target. Joiner et al. states that almost all of the photons produced by linear
accelerators have sufficient energy to cause ionizations, but most biological
damage is done by the ejected electrons themselves, which go on to cause
further ionizations in the molecules they collide with, progressively slowing down
as they go (Kogel, 2009). The charged particles (electrons, protons etc.) are
called directly ionizing and the uncharged particles (photons) are characterized
as indirect. Unlike the three main interactions of photons (indirectly ionizing)
discussed above, the electrons (directly ionizing) will interact with matter in three
ways.
Soft collision: this type of interaction is denoted in Figure 0-1: (b>>a) will
occur when the charged particle passes an atom in matter at a considerable
distance. The net effect is the transfer of a very small amount of energy to an
atom of the absorbing medium (Frank Herbert Attix, Charged-Particle
Interactions in Matter, 1986). b in the figure denotes the impact parameter and a
is the radius of the atom.
Hard Knock-on collision: this type of interaction occurs when the impact
parameter b is approximately equal to the radius a. The incidence charged
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particle will interact primarily with a single atomic electron, which is then ejected
from the atom with a considerable kinetic energy (Frank Herbert Attix, ChargedParticle Interactions in Matter, 1986). These types of collisions occur far less
than the soft collision (Figure 0-1:).
Coulomb-force interaction: this type of interaction occurs when the impact
parameter b<<a (Figure 0-1:). This would occur when the incoming charged
particle interacts with the Coulomb force of the nucleus. The electron is
scattered elastically and does not emit an x-ray photon or excite the nucleus
(Frank Herbert Attix, Charged-Particle Interactions in Matter, 1986). Because
the electron loses a very small (often insignificant) kinetic energy, this
mechanism is not for the transfer of energy to the absorbing medium, but it is an
important means of deflecting electrons (Figure 0-1:) (Frank Herbert Attix,
Charged-Particle Interactions in Matter, 1986).
As charged particles traverse a medium, the expected value of the rate of
energy loss per unit length is defined as stopping power. To be more specific:
collisional or radiative stopping power. Where collisional stopping power is the
sum of all energies lost due to soft and hard knock-on collisions, and radiative
stopping power is simply the energy lost due to radiative interaction (b<<a). The
collisional stopping power will depend on , the velocity of the particle itself, and
the charge of the particle. In short, the collisional stopping power will decrease
with increase Z of the medium (in clinical setting this would be tissue, bone etc.).
Consequently, the collisional stopping power will increase when the velocity is
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small. Lastly, an increase in particle charge will quadruple the collisional
stopping power.

Figure 0-1: Charge particle collisions- (Attix, 1986)

Radiotherapy in medicine has evolved extensively starting from the basic Xray generators that were used for superficial treatments to our current Linear
Accelerators used for deep seated targets. For this dissertation, I will focus on
linear accelerator radiotherapy. A linear accelerator often referred to as a “linac”
is a sophisticated device that accelerates charged particles to treat with
electrons or gamma rays. Today, tumors are mainly treated with three types of
particles: electrons, protons and photons. As described above, these types of
directly or indirectly ionizing particles will interact with matter differently, but for
this dissertation, I will focus on external beam photon and proton radiotherapy.
1.2

Photon and Proton Radiotherapy

9
Prior to discussing radiotherapy techniques, let us first discuss how photons
and protons are produced.
Although there are several types of linear accelerators that are capable of
producing photons, the most relevant and extensively used in clinical
radiotherapy utilizes waves of 3GHz frequency, also known as S band.

Figure 0-2: Typical radiotherapy linear accelerator

Figure 0-3: Typical Accelerator tube
The main components of a linear accelerator include (Figure 0-2:): power
supply, modulator, Magnetron/Klystron, accelerating structure, electron gun, and
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treatment head (Faiz Khan, Clinical radiation Generators, 2003) (Williams,
1997):


The power supply is used to provide direct power to the modulator



The modulator’s main function is to supply negative-going high-voltage
pulses

to

the

cathode

of

the

microwave

generator

valve

(klystron/magnetron) and the electron gun.


The magnetron is a microwave generator that is fed into the accelerating
guide with a set frequency. Most magnetrons operate at a peak power of
5MW.



The Klystron is a microwave amplifier.

Unlike magnetron, linacs that

utilize a klystron have a low power oscillator that drives the klystron itself.
In short, klystron utilizes a hot wire cathode (negatively charge) that
produces electrons which are accelerated by a negative pulse of voltage
into the first cavity, called the buncher cavity, which is energize by lowpower microwaves. The microwaves set up an alternating electric field
across the cavity. The velocity of the electrons is altered by the action of
this electric field to a varying degree by a process known as a velocity
modulation. Because some electrons are sped up while some are slowed
down, it results in bunches of electrons. As these electrons arrive at the
anode (positive charged) side of the klystron, they will induce charges
therefore generate a retarding electric field. The electrons suffer
deceleration and by the principal of conservation of energy, the kinetic
energy of the electrons is converted into high-power microwave that will
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make its way to the accelerating structure (Faiz Khan, Clinical radiation
Generators, 2003).


Accelerating structure is an evacuated copper made tube with unequally
spaced disks. Electrons are injected into this structure from the electron
gun. They will interact with the electromagnetic field of the microwaves,
which will allow them to gain energy as they traverse along the structure
and out into the exit window of the structure (Figure 0-3:).



The electron gun can be separated as diode or triode. Its main purpose is
to create electrons that will be accelerated into the accelerating structure.



The treatment head is comprised of several bending magnets and energy
selection slits that would ensure the electron pencil beam to be well
focused as it exits. Additionally, another main component in the treatment
head is the target. The target is utilized for photon production. Further
beam shaping devices like flattening filters, scattering foils, multi leaf
collimators (MLC), metallic jaws etc. are used to further collimate the
beam for clinical treatments. Other important components in this
particular section of the linear accelerator are the ion chambers. The ion
chambers allow for continual output verification of the beam and other
parameters like flatness and symmetry.

The linear accelerators used in most clinics across the United States have
the option to deliver either photons or electrons to the patients. Photons are
predominantly used for deep seated tumors, whereas electrons are mostly for
superficial targets. The photons in the linear accelerator are created by
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accelerating electrons in the manner described above and then “smashing”
them into a high Z target. This will allow the electrons to go through the
bremsstrahlung interaction (Section 1.1) and consequently generate photons.
For the electron beam, the target is moved away from the beam path.
For proton radiotherapy most clinics, will use a cyclotron. A typical design of
the cyclotron is depicted in Figure 0-4:. The cyclotron utilizes a proton source
(H+) that is confined into a spiral shape by two D shaped electrodes, one
positively charged and the other is negatively charged. A physical gap is created
in between the two Ds. A magnetic field is applied perpendicular to the “Ds”,
and as protons travel through one D and into the other the electric field is
switched leading to an increase in velocity and consequently the path trajectory
will increase as described in (Figure 0-4:). The final velocity at the exit window
is directly correlated to the radius of the double Ds by the following equation:
(6)

=
Where
radius.

is charge,

is particle mass,

is magnetic field applied and

is the
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Figure 0-4: Typical Cyclotron (https://atomic.lindahall.org/what-is-an-atomsmasher.html)

As the proton particles exit the cyclotron window, they are magnetically
guided into a final exit window. Contrary to the electron particles, protons are
heavy charged particles which result in minimal scatter and therefore they
exhibit a low entry dose, an increase of dose near the end of their range and a
sharp exit dose. Such unique property allows protons to play an important role in
radiotherapy and uniquely compliment electrons and photons. Depth dose
curves that figuratively represent these unique properties of photons, electrons
and protons are denoted in (Figure 0-5:).
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Figure 0-5: Depth Dose curves for photons, protons and electrons
The sharp increase of dose at the end of the proton range is defined as the
Bragg peak. The width of the Bragg peak is often too narrow, as indicated in
(Figure 0-5:), for most clinically observed targets in radiotherapy, as a result its
modulation, also known as SOBP (spread out Bragg peak) is often necessary.
Bragg peak modulation can be achieved by either switching beam energies or
by introducing a modulator in the beam path. In either case, the weighted
combination of all the peaks results in a flat dose distribution that is practical for
uniformly treating deep seated targets.
1.3

Thoracic Radiotherapy Treatment Techniques

Thoracic targets are currently being treated with either photons or protons.
Photon radiotherapy techniques consist of: Three Dimensional Conformal
Radiotherapy (3DCRT), Intensity Modulated Radiotherapy (IMRT) and/or
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Stereotactich Body Radiotherapy (SBRT) and for proton: pencil beam scanning
(PBS) and passive scattering proton therapy (PSPT).
3DCRT techniques utilizes a CT (computed tomography) and a limited
uniform photon beams that are delivered with static gantry and MLC shapes (or
blocks).
IMRT utilizes the MLCs for beam shaping and modulation. The MLCs
produce intensity maps with dozens of beamlets within one field whose
intensities are independent of one another. IMRT plans are usually identified as
static or VMAT/RapidArc IMRT. For a static IMRT, the gantry is stationary, but
the MLC leaves will move while the radiation beam is ON to create the intensity
modulated beam. For VMAT/RapidArc, the gantry is simultaneously rotating
around the patient as the MLCs modulate the beam around the patient.
SBRT, unlike conventional radiotherapy, is a treatment technique that
delivers fewer fractions of radiation (usually less than 5), but in a much higher
dose. SBRT can be delivered either with 3DCRT or IMRT/RapidArc/VMAT,
however clinicians tent to choose the latter, due to its ability to modulate the
beam and conform the dose around the target better than 3DCRT.
PBS utilizes a few-millimeter (1 to 4 mm) pencil beam that is raster scanned
across an area one spot at a time. Once the scanning is complete, the beam
energy is changed to scan the next layer (depth). The most distal layer of the
target is scanned first. PSPT relies on primary and secondary scattering
material to create a 3D conformal dose distribution in the target. PSPT
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technique is limited to a predesignated SOBP modulation, which must cover the
full motion range of mobile targets.
For any of the above modalities, the patients with thoracic tumors will
undergo an initial simulation. This entails placing the patient on the flat CT
couch with an upper body immobilization and arms above their head. They are
subsequently imaged via the CT scanner and the 3-dimensional images are
used to create a computerized treatment plan with one of the three modalities
previously described. The CT scanner uses a fixed X-ray and detector panel
that rotates around the patient, and the detector panel records the X-ray that
exits the patients’ body. As the X-ray unit rotates around the patient, it will
collect static images for each angle before it moves to a different section of the
body. This is defined as a “slice” which runs along the superior to inferior
direction of the body. Once all the desired slices are imaged, a mathematical
algorithm is applied to create a 3-dimensional image with the appropriate
electron density values, which is consequently used for treatment planning. For
thoracic targets that are mobile, 4DCT is utilized. 4DCT introduces time as its
fourth component. Like conventional CT, patients are scanned slice by slice
utilizing the same X-ray source and detector, but each location is scanned for at
least one breathing cycle. A mathematical algorithm is then used to bin all the
slices based on the respiratory phases (or amplitude).
In any thoracic radiotherapy plan, the critical structures and targets are
defined (contoured) by the planner and Radiation Oncologist respectively.
Contours allow the treatment planning algorithm to optimize gantry angles, MLC
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intensity modulation and other parameters such as desired dose to the target
and OAR (organs at risk). CT imaging, as previously described, is simply a
snapshot of the patient, at a particular time; as a result, organ motion is not well
quantified, therefore 4DCT is often the imaging technique of choice. Due to
spatial limitations of the scanner, limited information on target motion as well as
setup uncertainties, several standard target definitions have been established by
the International Commission on Radiation Units and Measurements (ICRU)
Report 62, a supplement of ICRU 50 (Figure 0-6:) (ICRU 50, 1993; ICRU 60,
1999).
The initial target will be contoured as GTV (gross tumor volume) which
implies that the target was defined by the physician through visualization or
palpation. Subsequently an expansion margin is applied to create a CTV
(clinical target volume). This expansion accounts for any subclinical involvement
that is too small to see due to the limited spatial resolution of the CT scanner.
Additionally, an internal margin (IM) is applied to the CTV to create ITV (internal
target volume). This expansion allows for possible mobility of the target itself
and often directly identified by the 4DCT. Lastly, a setup margin is applied to the
ITV to create PTV (planning target volume). This margin will account for any
setup errors that may occur during daily treatments. The PTV is often the final
definition of a target that the planner will use to create the computerized
treatment plan, in addition to contouring all of the organs at risk that are next to
the PTV or in the beam path.
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Figure 0-6: ICRU 50/62 target definition (ICRU 60, 1999)
1.4

Management of Respiratory Induced Tumor Motion
Improvements in radiation delivery techniques (Armstrong, 1993) of thoracic

targets enable clinicians to achieve conformal dose delivery, while limiting dose
to the OARs. However, the motion of a target continues to be a challenging
parameter.

The

International

Commission

on

Radiation

Units

and

measurements (ICRU) Report 50 (ICRU 50, 1993) and the Supplement Report
62 (ICRU 60, 1999) describe the current recommendation for incorporation of
tumor motion into radiation therapy planning. In the thorax, targeting is
complicated by respiratory motion, which can cause tumor displacements as
large as 2 cm during treatment (Shimizu, et al., 2001) (Seppenwoolde, et al.,
2002).
Accurate targeting is critical, particularly for mobile tumors that are treated
with SBRT. The American Association of Physicist in Medicine (AAPM) Task
Group 76a report on the management of respiratory motion in radiation
oncology (Keall, et al., 2006), recommends margins around the treatment target
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be sufficient to ensure coverage of the target. In a landmark SBRT trial for early
stage inoperable lung cancer, Timmerman, et al. used planning target volume
(PTV) expansions from the gross tumor volume (GTV) of up to 5 mm in the
axial dimension and 10 mm in the cranial-caudal (CC) direction (Timmerman, et
al., 2010). This relatively large PTV expansion in the CC direction results in a
larger volume of healthy tissue being irradiated.
For thoracic malignancies 4DCT provides a snapshot of the respiratory
induced tumor motion which is used to individualize the internal target volume
(ITV) (Pan, 2004), yielding smaller treatment margins than fluoroscopy. As
4DCT scanning and image-guided radiotherapy (IGRT) became more readily
available, recent studies have reduced the PTV margins to a 5 mm uniform
expansion around an ITV that accounts for respiratory motion (Liang) (Li X. e.)
(Kilburn, 2016).
1.5

Respiratory Management Techniques
There are several motion management techniques that are utilized in the

clinic to track or reduce tumor motion to meet the national recommendations
and guidelines mentioned above. They include, but not limited to: abdominal
compression, respiratory gating, respiratory tracking, breath hold, active
breathing coordinator (ABC) and jet ventilation.
External abdominal compression technique is one way to control (compress)
tumor motion. This technique utilizes a full or partial vac-lock body bag for
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external patient immobilization and an abdominal compression plate (Figure
0-7).

Figure 0-7: Example of Full Body Vac-Lock with abdominal compression plate
The patients’ abdomen is compressed with an external plate for both imaging
and treatment. The downside of this technique for lung cancers continues to be
its inconsistency and minimal dosimetric gain for lung sparing (Bouilhol, et al.,
2013).
Respiratory gating (Keall , Kini, Vedam , & Mohan, 2002) (Kubo, 1996) and
tracking (Shirato H. e., 2000) (Keall e. a., 2006) (Hospital, 2015) (Shirato H. e.)
have been used to reduce the uncertainty in tumor targeting thereby reducing
the free tissues irradiated. Both techniques have been previously used to lower
the uncertainty in tumor targeting, therefore reducing the PTV margins. Such
margin reduction benefits were presented by (Keall , Kini, Vedam , & Mohan,
2002). They investigated gating for treatment margins, image artifacts and
volume for a spherical moving object. In that study, during the CT imaging of
dynamically moving spheres, gating reproduced the static volume to within 1%
whereas errors of over 20% were observed where gating was not used (Keall ,
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Kini, Vedam , & Mohan, 2002). Furthermore, Keall et al., (Keall e. a., 2006)
noted that gating can reduce margins from CTV to PTV by as much as 2 to11
mm. However, the downfall of these methods can often be associated with low
Duty Cycle (DC) (Eq. 7), also known as the beam ON time, and accuracy of
predictive filters.
Breath-hold gating techniques have been widely used in radiotherapy
(Wong, 1999). One such technique is voluntary breath hold. The patient is
coached to inhale and hold their breath. This technique has its limitations and
therefore has not received widespread adoption due to the breath-holding
capacity limitation of patient (10 – 20 sec). The second technique is ABC, a
device and treatment method developed at William Beaumont Hospital which
provides non-invasive internal immobilization of anatomies affected by
respiratory motion, such as the breast and lung [20]. This is achieved through
comfortable, simple and efficient assisted breath-hold techniques. Patient breath
volumes are monitored, and the airway is closed as a fixed inspiratory volume
for the duration that the patients holds the breath-hold button (Figure 0-8:). The
ABC has been widely used for stereotactic treatment in the lung and has been
proven effective in clinical practice for more than 15 years (Boda-Heggemann,
2016). The intra-fraction reproducibility for repeat breath-holds has been
reported to be ≤ 2 mm (Glide-Hurst, Gopan, & Hugo, 2010). However, like
breath holds, its use is limited to patients who are physiologically capable of
breath-holds. Many lung cancer patients can not tolerate breath-holds.

22

Figure 0-8: A simulated patient demonstration of the ABC breath-hold. The
machine allows reproducible assisted breath-holds at similar volumes between
breath-holds by use of spirometer to measure tidal volumes.
Lastly, jet ventilation was reported for respiratory motion immobilization for
use in intubated patients who received general anesthesia (Herfarth, 2000). This
technique was limited to patients who were treated in a single fraction. Robotic
tumor motion tracking using external surrogate markers has been reported for
SBRT treatment of lung tumors (Schweikard). This technique treats continuously
while the patient breathes freely (Seppenwoolde Y. e., 0094-2405), however is
limited to the CyberKnife and now Radixact robotic treatment device. An ideal
respiratory motion compensation method that has a high duty cycle (Eq. 7), will
provide the patient comfort of free breathing, while not requiring special
radiotherapy equipment.
1.6

Motivation for the Project
High frequency percussive ventilation (HFPV) is a novel immobilization

technique that has gained little attention in radiotherapy. It utilizes high
frequency low tidal volume ventilation to produce endotracheal percussion
(Salim A. a., 2005) (Allan, Osborn, Chung, & Wanek, 2010). The device is an
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adaptation of a pneumatic high frequency ventilator in which high flow jets of
gas are delivered to the airways by a flow interrupter called a Phasitron.
Activation of the venturi system within the Phasitron creates bursts of gas at
frequencies of 100 to 400 bursts per minute within a tightly controlled ratio of
gas delivery and passive exhalation. The device is used for mobilization and
clearance of pulmonary secretions. HFPV improves oxygenation versus
conventional ventilation, with no barotrauma, in patients with acute respiratory
distress syndrome (Spapen, 2014) (Gallagher, 1989).
HFPV is designed to treat active pulmonary disease and to prevent the
development of disease caused by secretion retention in either intubated
sedated patients or spontaneously breathing awake patients. For example,
HFPV was found to prevent deterioration in patients with acute exacerbation of
COPD [30]. It is tolerated well enough for use in the pediatric outpatient setting
in cooperative alert patients (Reardon, 2005).

Figure 0-9: A graph of chest wall circumferential strain measured with an Anzai
respiratory belt during free breathing period, onset of HFPV, and during the
apneic-like HFPV period adapted from Peguret et al. (Peguret N. a.-d., 2016)
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Recently, high frequency percussive ventilation (HFPV) was reported for
immobilization of thoracic tumors for imaging (Prior J. e., 2016) and stereotactic
body radiotherapy (SBRT) [33]. In Peguret’s SBRT study, thoracic tumor
respiratory motion was inferred from changes in the chest diameter measured
by an Anzai respiratory belt (ANZAI Medical Co, Tokyo, Japan). A sample trace
of the thoracic diameter from Peguret et al (Peguret N. e., 2016) is shown in
Figure 0-9:. There were patients who could not tolerate percussive ventilation
assisted breath-holds for greater than 10 to 15 seconds. This preliminary study
provided no direct evidence of tumor motion reduction and no evidence of intrasession reproducibility. Filling this gap in knowledge is an important
consideration before moving HFPV into clinical practice for tumor immobilization
for proton or photon therapy.
1.7

Hypothesis
o HFPV provides direct tumor immobilization of <5 mm for all targets
exhibiting respiratory motion >10 mm
o HFPV provides reproducible thoracic immobilization with <5 mm residual
motion, over 1-minutes intervals with rebreathing between each instance.
o Significantly reduces the interplay effects noticed in pencil beam
scanning proton radiotherapy.
o HFPV can significantly reduce the PTV margin for thoracic targets and
subsequently healthy tissue toxicity

1.8

Set Objectives
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o The primary objective of this study is to test if HFPV can be a
viable method for thoracic immobilization
o A second primary objective is to evaluate if HFPV can reduce lung
tumor motion from ≥ 10 mm to < 5 mm. This will be the first study
to directly measure tumor motion reduction using HFPV.
o A second objective is to evaluate the reproducibility of HFPV
immobilization. Will the target return to the same location after rebreathing then repeat HFPV?
o Another secondary objective is to evaluate the interplay and
dosimetric effects of HFPV motion.
CHAPTER 2: HIGH FREQUENCY PERCUSSIVE VENTILATION
PROTOCOL
1.9

Introduction

This is a prospective trial of 15 volunteers and 10 patients with thoracic tumors
that were utilized to develop our first experience with HFPV for thoracic tumor
immobilization. The study was separated into two main cohorts. Cohort I
entailed the recruitment of 15 healthy volunteers who underwent HFPV while
monitoring for chest wall motion. Cohort II consisted of 10 patients with
conspicuous thoracic tumor whose motion was identified to be greater than 10
mm.

Cohort I, II
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Cohort I

15 Volunteers

Up to five <1 hour
session w/ HFPV

Cohort II

10 Patients with
thoracic tumor
motion > 1cm

1 hour training
session w/ HFPV

45 sec Fluoro with
+/- HFPV @ -1, 0,
5, and 10 Mins

Figure 0-1: Study Cohorts & Scheme. Fifteen normal volunteers were recruited
to gain familiarity with the HFPV device and monitoring equipment. Ten patients
with conspicuous thoracic tumors that move ≥ 10 mm due to respiration on their
treatment plan
All 10 patients would undergo fluoroscopic imaging while in free and HFPV
breathing (Figure 0-1). Subsequent follow up studies were performed to validate
the clinical and dosimetric impact of the data obtained from the above cohorts.
1.10 Methods
1.10.1 Cohort I: Eligibility, Recruitment and Selection
1.10.1.1.1
nclusion Criteria

I

Volunteers must be older than 18 years of age and must be able to sign
consent.
1.10.1.1.2
xclusion Criteria


Volunteers unable to tolerate the 1-hour sessions with HFPV.



Volunteers with history of COPD or pneumothoraxes.



Volunteers with hemoptysis.



Volunteers requiring supplemental oxygen.



Volunteers with fractured rib or unstable chest

E
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Volunteers with who report a known panic or anxiety disorder.



Volunteers who are pregnant or who think they may be pregnant.



Unable to sign informed consent due to cognitive impairment or health
status.



Patients who are <18 years old.

1.10.1.2
tudy evaluation

S

The volunteers will be evaluated lying supine and flat on the treatment bed
with their arms above their head. Their chest wall motion will be monitored using
the Anzai Respiratory Monitor (Anzai Medical Co, Tokyo Japan). The device,
which has FDA 510(k) clearance, makes no contact with the subject, using a
laser and detector to monitor motion. Volunteers will undergo trial periods of
HFPV using various interface devices – mouthpiece, face mask, nasal prongs,
each evaluated for compliance and ease of use. The volunteer sessions will be
completed within 1-hour time and may be repeated up to 5 times for a single
volunteer. After each session, the volunteer will be asked to complete a
feedback questionnaire
1.10.1.2.1
FPV

H

The Percussionaire IPV-2C (Percussionaire Corp., Sagle, Idaho) is a
pneumatic (air driven) device that delivers both continuous positive airway
pressure (CPAP) and mini bursts of air. This combination allows air to enter
behind mucus blockage, and vibration to dislodge mucus from the airway walls
so it can be more easily coughed up. The Phasitron® uses a unique, patented
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venturi as a “clutch” mechanism to protect the lung from over pressure. A
biofilter is placed between the Phasitron and the patient. A video showing the
home use of percussion ventilation in a cystic fibrosis pediatric patient is
available on-line (https://www.youtube.com/watch?v=FpSicdEZOhw).
During this component we will compare use of various respiratory interfaces
to volunteers (native Phasitron mouthpiece, ABC mouthpiece shown in Figure
0-8:, face-masks, nasal prongs), respiratory settings, and chest wall motion. The
nasal prongs and the active breathing control breathing tube (mouth piece) are
used as one single unit during the administration of the percussive breathing.
The face mask is a secondary testing piece that will be used on all volunteers as
well. We will evaluate for ease of use, comfort, minimal motion, geometric
interference, and compliance. We will seek to maximize comfort, minimize chest
wall motion, maximize duration of apneic-like HFPV state, ease of use and
reproducibility.
There are no reports of which, we or Percussionaire Corp., are aware that
indicate an increased incidence of barotrauma or pneumothorax associated with
high frequency percussive ventilation (HFPV). For example, one randomized
trial comparing HFPV versus low tidal volume ventilation (LTV) in burn injury
patients with acute lung injury found no HFPV patients developed barotrauma
versus four who received LTV (p =0.04) (Chung, 2010). There are reports on the
use of percussive ventilation to treat pneumothorax in an infant with
osteogenesis imperfect (Nino, 2009) and in adult post-surgical patients with
persistent pneumothoraxes (Gatani, 2010). In order to be on the safe side, we
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will consider risk factors for pneumothorax following CT-guided thoracic biopsy.
The risk of pneumothorax requiring chest tube placement following CT-guided
needle biopsy increases with emphysema present on CT (Laurent, 1999) and
severe COPD (COPD stage GOLD 3 or greater (Vestbo, 2013). Severe COPD
is identified with an FEV1 < 50% predicted value. In this study we exclude
patients with history of pneumothoraxes, emphysema present on the RT
planning CT, or FEV1 < 50% predicted value.
The duration of the HFPV administration depends on the comfort level of the
individual subject. The goal of the session is to achieve greater than 5 minutes
of lung immobilization under one hour of the training session. We will ask for
feedback from the volunteer. This will assist us in developing the best tolerated
and technical technique for the patient cohort. After this cohort, we will evaluate
the data and the feedback to test in the patient setting of Cohort II.
1.10.1.2.2
nzai Respiratory Motion

A

The Anzai AZ-733VI (Anzai Medical Co, Tokyo Japan) is an FDA approved
device utilized in gated radiotherapy treatment and diagnostic PET/CT. The
business card size laser/sensor measures the reflection of laser light (infrared)
from the patient's skin, and the motion of the body surface (displacement of
distance to the sensor) is recorded on the device computer. Volunteer and
patient respiratory trace records will be anonymized and recorded using patient
study number. IRB Both volunteers in cohort 1 and patients in cohort 2 will have
their chest wall motion monitored for the duration of the training and
experimental sessions (≤ 1 hours total each session).
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1.10.1.2.3
xygen and Carbon Dioxide Supply

O

The SenTec Digital Monitoring System (SDMS) provides continuous and
noninvasive real-time monitoring of transcutaneous CO2 partial pressure (tcPCO2), functional oxygen saturation (SpO2), pulse rate (PR), and pulsation
index (PI) in adult and pediatric patients. A small dime size transducer is
attached with a postage-stamp sized adhesive behind the subject’s ear for
monitoring. Both cohorts of patients will receive monitoring of tc-PCO2, SpO2,
and PR during the training and experimental sessions.
1.10.2 Cohort II: Eligibility, Recruitment and Selection
1.10.2.1.1
nclusion Criteria


I

Patients with conspicuous lung tumor that exhibit greater than 10 mm
motion on their radiotherapy planning 4DCT. Patient lung tumors must be
visible on the AP CT projection scout.



Patients must sign informed consent to enter this study.



Documented not pregnant if child-bearing age woman.

1.10.2.1.2
xclusion Criteria


E

Patients unable to tolerate the 1-hour training and 20-minute imaging
sessions (RT fluoroscopy).



Patients with history of pneumothoraxes, emphysema present on RT
planning CT, or FEV1 < 50% predicted value.



Patients with hemoptysis.



Patients requiring supplemental oxygen.
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Patient with fractured rib or unstable chest



Patients with a known panic or anxiety disorder



Unable to sign informed consent due to cognitive impairment.



Patients who are <18 years old.

1.10.2.2
tudy Evaluation

S

1.10.2.2.1
FPV

H

The Percussionaire IPV-2C and Phasitron are described above. Patients in
cohort 2 will receive a 1-hour training period with the HFPV device to minimize
thoracic motion. They will then be brought to the RT treatment room where the
on-board imaging device will be used to provide fluoroscopy. They will undergo
45 sec of fluoroscopy at 4 time points, one before with tidal breathing, one at the
start of the HFPV, one after 5 minutes, and one after 10 minutes of using the
IPV-2C. Patients will be allowed to rebreathe in between these fluoroscopy
procedures.
1.10.2.2.2
nzai Respiratory Monitor

A

Patients in cohort 2 will have their chest wall motion monitored for the
duration of the training and experimental sessions (approximately 1 hour 15
minutes total). There is no direct contact with the patient, only a low power laser
light is displayed and tracked on the patients’ skin to measure chest wall skin
motion.
1.10.2.2.3
enTec

S
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The SenTec Digital Monitoring System (SDMS) will provide continuous and
noninvasive tc-PCO2, SpO2, and PR monitoring during the HFPV sessions. A
small dime size transducer is attached with a postage-stamp sized adhesive
behind the subject’s ear for monitoring. A digital record is kept under the
patient’s study number.
1.10.2.2.4
T Fluoroscopy

R

RT Fluoroscopy. The Elekta treatment machines have an on- board kV
imaging system consisting of a low power diagnostic x-ray tube and a flat panel
detector capable of imaging at 10 Hz. Patients will undergo one session of
fluoroscopy before with tidal breathing, at onset of HFPV, at 5, and 10 minutes
after onset. The patients will be allowed to rebreathe between the repeat
fluoroscopy acquisitions. The tumor volume will be auto-segmented frame-byframe using image intensity-based registration algorithm to ascertain the degree
of the tumor motion
1.11 Analysis and Risks
1.11.1 Criteria for Study Removal
Healthy volunteers and patients unable to tolerate HFPV process due to
discomfort or for any other reason. Subject (healthy volunteer or patients) choice
(subjects can withdraw from the study at any time, for any reason). If subjects
experience any of the following, shortness of breath, chest pain, increased
oxygen requirement (pulse ox <88%), significant change in heart rate
(>110bpm), fatigue, or vomiting, the patient will be evaluated by the radiation
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oncologist. At this point, the study procedures will be stopped, and the subject
participation will be completed. Data already acquired may evaluated within the
study, including information related to the adverse event if attributed to the
study. Study will be put on hold and evaluated by the ISMC if 2 of the first 5
subjects cannot complete the first 1-hour session. Evaluation will determine if a
revision of study or the discontinuation of the study is necessary.
1.11.2 Registration procedure
Informed consent is required prior to participation in this study. The study
coordinator will inform potential subjects about the study opportunity and ask if
they would like to participate. If the patient is interested, they will be given an
opportunity to read the informed consent and authorization document specific to
the study and ask questions of the study coordinator. The patient will be
informed about: 1) the rationale for the study; 2) the logistics of the study; 3) the
risks of the study; 4) how the data will be used. Consent will be obtained by the
study coordinator. The patient will be given a copy of the consent and asked to
sign another copy for our records.
Patients will be registered for the study after pretreatment evaluation is
completed and eligibly criteria are met. The principle investigator and all key
personnel have completed NIH approved institutional and HIPAA training in the
conduct of medical research studies.
1.11.3 Potential Risks
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Two cohorts will be recruited for enrollment in this study, volunteers and
patients with thoracic tumors that move ≥ 1 cm. The participation in this study for
the cohort 1 volunteers will consist of no more than 5 sessions of HFPV while
their chest wall motion is monitored. Their risk is solely due to HFPV. For cohort
2 patients their risk will be from HFPV and RT Fluoroscopy. The total dose per
patient for this study is estimated at 28 mSv per patient in cohort 2. This dose is
less than the Radiation Safety Committee guidelines of 50 mSv per year from
research.
The volunteers and patients recruited to this study will receive HFPV while
monitored for O2 saturation and transcutaneous pCO2. The HFPV is powered
from the hospital supply O2 and delivers a mixture of O2 and room air. Patients
may experience increased shortness of breath, chest pain, an increased O2
requirement, change in heart rate or rhythm, blood pressure, fatigue, or emesis
and panic. Risks also include under/over ventilation, under/over humidification,
pneumothorax, pneumomediastinum, PIE, pneumoperitoneum, and hemoptysis.
Volunteers or patients who experience any of these symptoms will be evaluated
by a physician and discontinued from the study.
RT Fluoroscopy Cohort. The major risk from the RT fluoroscopy imaging is
from the radiation. The dose equivalent for this device is estimated at 1 mSv/10
sec beam time. The RT fluoroscopy imaging will deliver approximately 28 mSv
total dose to the patient.
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CHAPTER 3: ESTIMATION OF CHEST WALL MOTION REDUCTION
WITH HFPV – PROSPECTIVE STUDY
1.12 Abstract
Purpose: High frequency percussive ventilation (HFPV) employs high
frequency low tidal volumes (100- 400 bursts/min) to provide respiration in
awake patients while simultaneously reducing respiratory motion. The purpose
of this study is to evaluate HFPV as a technique for respiratory motion
immobilization in radiotherapy.
Methods: In this study fifteen healthy volunteers (age 30y-75y) underwent
HFPV using three different oral interfaces. We evaluated each HFPV oral
interface device for compliance, ease of use, comfort, geometric interference,
minimal chest wall motion, duty cycle and prolonged percussive time. Their
chest wall motion was monitored using an external respiratory motion laser
system. The percussive ventilations were delivered via an air driven pneumatic
system. All volunteers were monitored for PO2 and tc-CO2 with a pulse oximeter
and CO2 Monitoring System.
Results: A total of N=62 percussive sessions were analyzed from the external
respiratory motion laser system. Chest-wall motion was well tolerated and
drastically reduced using HFPV in each volunteer evaluated. The average peakto-peak motion for free breathing was 8.14 mm (median: 6.90 mm, range: 2.70
mm – 18.6 mm) and for HFPV was 2.52 mm (median: 1.80 mm, range: 0.60 mm
– 8.40 mm)
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Conclusion: We believe HFPV may provide thoracic immobilization during
radiotherapy, particularly for SBRT and pencil beam scanning proton therapy.
1.13 Introduction
Improving immobilization and delivery techniques for thoracic tumors
continues to be essential in radiotherapy; particularly for patients undergoing
stereotactic body radiotherapy (SBRT), hypo-fractionated regimens and pencil
beam scanning proton therapy.

Unlike photon radiotherapy, pencil beam

scanning proton radiotherapy consists of a 2 to 3-millimeter spot that is “raster”
scanned across the target one slice at a time. The pencil beam is moved across
the field with the aid of fast and slow magnets. The depth is achieved by a range
modulator that alters the proton beam energy, shifting the range and Bragg
Peak (Newhauser, 2015).
For stationary targets, the pencil beam scanning proton therapy scans
across each slice and creates a highly conformal dose deposition throughout the
target. However, significant in-homogeneities have been noted for targets that
move during pencil beam scanning proton therapy due to interplay effects
(Langen K. a., 2001) (Shirato H. e.) (Bert C. a., 2008) (Seppenwoolde, et al.,
2002). Bert et al. (Bert C. a., 2008), reported that the homogeneity on their
radiographic films study was less than 80% for motion amplitudes of about 15
mm. The homogeneity for their treatment-planning study, based on patient data,
was on an average 71% for 95% of the target volume. Such drastic interplay
effects for targets that move during pencil beam scanning particle radiotherapy
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have prompted institutions to employ techniques that would allow for reduction
or monitor of target motion.
Undoubtedly the goal in radiotherapy planning continues to be its accurate
delivery of radiation to the target while maintaining good sparing of nearby
healthy tissue. However, acceptable distribution of absorbed dose within the
target could become compromised when they are mobile. As a result, the
International Commission on Radiation Units and measurements (ICRU) Report
50 (ICRU 50, 1993) and the Supplement Report 62 (ICRU 60, 1999) describe
the current recommendation for incorporation of the tumor motion into radiation
therapy planning. Subsequently, the American Association of Physicist in
Medicine (AAPM) Task Group 76a report on the management of respiratory
motion in radiation oncology (Keall, et al., 2006) recommends margins around
the treatment target be sufficient to ensure coverage of the target. Lastly, in a
landmark SBRT trial for early stage inoperable lung cancer, Timmerman, et al.
(Timmerman, et al., 2010) used planning target volume (PTV) expansions from
the gross tumor volume (GTV) of up to 5 mm in the axial dimension and 10 mm
in cranial-caudal direction. Several papers have been published on ways to
mitigate motion in order to achieve optimal dose distribution and comply with the
above recommendations. Abdominal compression can be inconsistent and in
cases increase target motion (Bouilhol G. a., 2013). Respiratory gating must rely
on accurate predictive filters and has low duty cycle (Verellen, 2010) (Murphy M.
J., 2004) (Keall, et al., 2006). Respiratory tracking can be invasive if fiducial
markers are used, but most importantly the correlation of the external surrogate
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(infrared tracking cubes or body surface tracking via stereo cameras) to internal
tumor may not be accurate (Ionascu, 2007) (Seppenwoolde, et al., 2002).
Breath hold relies on the ability of the patient to hold their breath during
simulation and treatment. As a result, such technique is often reserved for
patients who are physiological capable.
The obvious solution to the above challenges would be to immobilize the
target itself. High Frequency Percussive Ventilation (HFPV) employs high
frequency low tidal volume ventilation to generate endotracheal percussion. The
patient is connected to the Intrapulmonary Percussive Ventilation/Impulsator
(IPV) device (Percussionaire Corp., Sagle, Idaho) through the Phasitron and
mouth piece interface (Figure 0-1:). Initiation of the IPV device will allow the
Phasitron to deliver small bursts of air into the patients’ trachea. The frequency
of the air bursts can be 100 to 400 bursts per minute. The Phasitron is attached
to a water reservoir which reduces dry throat, in addition to providing a path for
carbon dioxide (CO2) to escape the lungs while continually oxygenating (Figure
0-2: and Figure 0-3:).

Figure 0-1: Percussionator - Intrapulmonary Percussive Ventilation/Impulsator
(IPV) 2C
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Figure 0-2: Phasitron

Figure 0-3: Phasitron and tubing
While HFPV is often used in bronchial hygiene therapy and other acute
respiratory diseases that allow for sustained improvement of oxygenation and
ventilation for such patients (Spapen, 2014), recently it was reported as a
technique to immobilize thoracic tumors for imaging purposes (Prior J. a., 2016)
and stereotactic body radiotherapy (Peguret N. a.-d., 2016).
In this study, we recruited fifteen healthy volunteers (age 30y to 75y) and
investigated various types of interfaces. The aim for this part of our study was to
evaluate each interface device for compliance, ease of use, comfort, geometric
interference, minimal chest wall motion, duty cycle and prolonged percussive
time.
1.14 Methods and Materials
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Fifteen healthy volunteers between October 2, 2017 and February 1, 2018
were enrolled in this Beaumont Research Institute Institutional Review Board
approved observational study (IRB# 2017-046). Each volunteer signed an
informed consent and were entered into the clinical research database prior to
the study entry. Volunteers that were unable to tolerate HFPV or required
supplemental oxygen, in addition to other medical concerns or pregnancy, were
excluded from the study. All volunteers were evaluated lying supine with their
arms above their head and a knee sponge for comfort.
Each volunteer was asked to undergo trial periods of HFPV using three
different types of oral interface devices: Amici Tru-Fit Mouthpiece Kit with tubing,
elbow and nose clips (Figure 0-4:), Fisher & Paykel Oracle 452 mask with
straps and nose clips (Figure 0-5:) and Phillips Respironics Oro-Nasal mask
with head gear (Figure 0-6:). Each interface connected to the Percussionaire
IPV-2C via the Phasitron and single use tubing kit.

Figure 0-4: Amici Tru-Fit mouthpiece interface
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Figure 0-5: Fischer & Paykel Oracle 452 interface

Figure 0-6: Phillips Respironics Oro-Nasal interface
The chest wall motion was monitored using Anzai respiratory monitor laser
system (Anzai Medical Co., Tokyo, Japan). The Anzai, is an FDA approved
system that utilizes a low power red laser which projects onto the patients'
surface. Each volunteer underwent at least one HFPV session per interface, but
multiple sessions were enabled. A typical example of two (Ns=2) HFPV
sessions per interface is denoted in Figure 0-7:
Python based code was developed to use Fourier transform for
decomposition of the breathing curves from the time domain into frequency
representation, as a validation to the manual IPV-2C dials. High peak indicates
the frequency that dominates the signal. The peak frequency was validated by
fitting on a cosine curve. The dominating frequency was validated against the
Percussionaire’s manual dial.
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Another important parameter evaluated was the duty cycle. Duty cycle is the
ratio of the amount of time that radiation delivery device is on
total treatment time (

+

relative to the

) (Eq. 6).

=

+

(7)

A threshold band (2 mm and 5 mm), highlighted in (Figure 0-13:) was
created for each of the Ns=62 HFPV sessions and duty cycle were calculated
for each threshold band.

Figure 0-7: An example showing what a typical signal would look like for patient
undergoing HFPV via one of the interfaces. Each volunteer undergoing HFPV
could've resulted in multiple HFVP sessions as indicated in this figure (Ns=2)
A small tcCO2 sensor from SenTec (SenTec AG, Therwil Switzerland) was
placed onto the volunteers' forehead. It is a non-invasive, transcutaneous device
that uses thin adhesive membrane attached onto the transducer to gather real
time data CO2, partial pressure (tc-PCO2), functional oxygen saturation (SpO2),
pulse rate (PR) and pulsation index (PI). All volunteers in this study were
monitored via SenTec device.
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We utilized the Percussionaire IPV-2C (Percussionaire Corp., Sagle, Idaho)
to provide HFPV bursts. The Percussionaire is pneumatic air driven device
(Figure 0-1:) that delivers continues positive airway pressure (CPAP) and mini
bursts of air (100 to 400 bursts/minute). The Phasitron is connected to the
Percussionaire via single use tubing kit. Distilled water was used to provide
moisturized air and prevent dry throat.
All volunteers (Nv=15) completed a Likert scale (1 strongly disagree - 5
strongly agree) subjective survey after each interface. Each subjective selfevaluating form consisted of eight linked questions separated into three main
domains (Table 1). First domain (Q1,2,5) assessed for comfort, geometric
interference and ease of use. Second domain (Q3,4,6,8) assessed for
compliance. Third domain assessed for explanation of procedure. All volunteers
were also allowed to provide written comments on each survey form.

The

duration and the number of HFPV sessions for each interface, was left at the
discretion of the volunteer. Trained and authorized medical personnel operated
all equipment.
Several statistical analyses were performed. A one-way Analysis of Variance
(ANOVA) test was used to compare mask and different scores on the Likert
scales. Additionally, a two-way ANOVA was performed to rule out interaction
between questions and mask. A paired t test was used to compare the
difference after. Kruskal Wallis test was performed to analyze duty cycle. A
Friedman test was utilized to rank the prolonged time for each interface.
1.15 Results
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All volunteers complied with the instructions and successfully completed
multiple sessions of HFPV for each of the three interfaces. All fifteen subjects
were able to participate for an hour-long session and hence were included in the
analysis. The amount of time each person was under HFPV sessions using
various masks were left to the discretion and tolerance of the subject. monitor
shows a typical setup of the Fischer Paykel Oracle 452 interface. We evaluated
the signals from the Anzai monitoring system for all fifteen volunteers. A total of
Ns=62 of HFPV sessions were analyzed.

Figure 0-8: Typical HFPV setup for Fischer & Paykel Oracle 452 interface with
nose clips and CO2 skin monitor
Significant maturation effects were noted during the first five volunteers with
both investigative team and patients learning the techniques involved in using
the interface and HFPV. Ns=25 sessions were recorded for the first five
volunteers, but fifteen of them were under sixty seconds. Subsequently, (Ns=37)
sessions were recorded for the last ten volunteers and only four of them were
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under sixty seconds. Due to these maturation effects in the first five volunteers,
only sessions from the last 10 volunteers were used to analyze aim two and
four. For aim two we analyzed one session per interface, per volunteer. Totaling
Ns=30. However, one session was excluded as a deviance, which we believe
was due to the geometrical fit of interface for the particular volunteer in neutral
position. For aim four we elected all sessions from the last ten volunteers
Ns=37.
The least square mean for Amici Tru-Fit, Fischer & Paykel Oracle 452 and
Phillips Respironics Oro-Nasal were 3.81, 3.74 and 4.01 respectively. The
second domain, represented by questions 3, 4, 6 & 8 on the survey, evaluated
for compliance. The least square mean for Amici Tru-Fit, Fischer & Paykel
Oracle 452 and Phillips Respironics Oro-Nasal were 2.48, 2.38 and 2.35
respectively. All three interfaces were reported favorably for comfort with Phillips
Respironics Oro-Nasal interface average score higher than the other two. On
the other hand, there was no statistical difference between the three interfaces
for compliance. The third domain, represented by question 7 on the survey,
evaluated for explanation of procedure. All three interfaces were scored very
high (5 out of 5), therefore excluded from analysis.

46

Table 1: Results from the subjective survey/questionnaire

Figure 0-9: Amplitude Distribution a)Range of % Ripple (peak to peak)
reduction while in HFPV b) Chest wall amplitude (peak to peak) for Free Breath
vs. HFPV as measured by Anzai
Our next aim was to investigate the chest wall motion reduction while under
HFPV for all Nv=10 volunteers. Ns=29 HFPV sessions were analyzed. A
temporal local mean reduction of 65.97% (Ns=29, median: 71.43 %, range:
14.29 %-87.50 %) was observed for the ripple magnitude (peak to peak)
between free breath vs. percussive (Figure 0-9:). A chest wall motion reduction
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was observed from an average of 8.14 mm (median: 6.90 mm, range: 2.70 mm18.6 mm) for free breathing to an average of 2.52 mm (median: 1.80 mm, range:
0.60 mm-8.40 mm) for percussive breathing. The mean difference before and
after HFPV was 6.59 (95% CI 5.09-3.06, p< 0.001). A multi variance regression
with significance for reduction in ripple percentage was significant for type of
interfaces and baseline ripple value.
The mean frequency of all the breathing curves from the Fourier
decomposition was 5.8839 cycles/second (353.03 cycles/min) for HFPV and
0.2252 cycles/second (13.51cycles/min) for free breathing Figure 0-10. This
was in agreement with the manual setting of the Percussionaire, which ranged
from 340-360 cycles/min and average free breathing of all volunteers between
10-15 cycles/min. HFPV and free breathing pattern was validated by fitting a
cosine curve, which was in agreement Figure 0-11.

Figure 0-10: Fourier transformation from time domain to frequency domain of all
chest wall curves obtained.
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Figure 0-11: HFPV and Free breathing validation by fitting the peak frequency
to a cosine curve
Out of Ns=62 HFPV sessions analyzed, the mean duty cycle for 2 mm
threshold band was 55.67 % (range: 14.00 %-100.00 %, median: 52.09 %).
Similarly, the mean duty cycle for 5 mm threshold band was 87.24 % (range:
31.85 %-100.00 %, median: 93.03 %). No statistical difference was noted
between the interfaces with both ANOVA and Kruskal Wallis test. A histogram of
both threshold bands is provided in (Figure 0-12:).

Figure 0-12: Duty Cycle distribution for each threshold band Ns=62 a) 5 mm b)
2 mm
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Figure 0-13: A typical chest wall motion recorded by Anzai detector. The initial
section indicates free breathing followed by HFPV
Lastly, we investigated prolonged percussive time for each volunteer. Out of
Ns=62, the average time in which the volunteers were under HFPV was 199.4
seconds (range: 9 sec-16.83 min, Upper 95% CI of mean: 258.8 sec, Lower 95
% CI of mean: 139.9 sec). Additionally, we investigated whether the prolonged
percussive time was statistically significant between the three interfaces. A total
of Ns=33 HFPV sessions from the last ten of the fifteen volunteers were
analyzed, Ns=11 for Amici Tru-Fit, Ns=11 for Paykel Oracle 452 and Ns=11 for
Phillips Respironics Oro-Nasal. Any percussive times less than sixty seconds
were omitted from the set calculations. A Friedman test resulted in statistical
significance between the three interfaces (p< 0.001). Mean for Amici Tru-Fit was
210.73 seconds (median: 174.00 sec, range: 60-570 sec, Upper 95%CI of
mean: 311.78 sec), mean for Fischer Paykel Oracle 452 was 360.00 seconds
(median: 273.00 sec, range: 107.00sec-897.00sec, upper 95%CI of mean:
524.05 sec), mean for Phillips Respironics Oro-Nasal was 400.73 seconds
(median: 258.00sec, range: 68sec-1010.00sec, Upper 95%CI of mean: 629.29
sec) (Table 2)
Interface/#sessions
in HFPV

Mean time in
HFPV (sec)

Mean DC 5 mm
band (%)

Mean DC 2 mm
band (%)
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Amici TruFit (Np=10,
210.73
82.20
43.93
Ns=11)
Fischer Paykel
360.00
79.09
39.24
(Np=10, Ns=11)
Phillips Respironics
400.73
78.96
48.75
(Np=10, Ns=11)
Total mean time in HFVP for Np=15, Ns=62(sec)
199.37 sec
Table 2: Duty Cycle (DC) and prolonged HFPV time for all three interfaces
1.16 Discussion
All the results obtained during this study were performed on healthy
volunteers. As a result, the reduction of chest wall motion and prolonged HFPV
times may not reflect that of a compromised patient.
We selected three different types of oral interfaces that have been previously
used in patients to mobilize and clear their pulmonary secretions. An average of
all HFPV sessions (Ns=62 from all Nv=15), from all three interfaces, showed that
the volunteers could tolerate percussions for an approximate average of 3
minutes to a maximum of 17 minutes. These times are promising and allow us
to further investigate HFPV as a tool for motion reduction in a typical 15-minute
radiotherapy appointment.
The CO2 levels for the first five volunteers were within normal ranges
therefore, we believe that providing detailed training to subjects and team will
play an important role in maintaining long, consistent and comfortable HFPV
sessions. Particularly for individuals that have no prior experience with aided
breathing.
Our first aim for this study was whether or not volunteers would be able to
comply with the procedure and subsequently provide feedback with regards to
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ease of use, comfort and geometric interference. As reported, all three
interfaces were favorable for comfort with Phillips Respironics Oro-nasal
interface means score higher than the other two. No volunteer indicated pain or
panic during the procedure. Almost all volunteers reported on the comment
section of each subjective survey, that Amici tru-Fit mouthpiece was the hardest
to hold in place during percussive ventilation due to lack of strap. Majority of the
volunteers commented that Respironics Oro-nasal rested well on their face and
introduced less dry throat than Fischer Paykel Oracle 452. However, they
indicated that they felt higher leakage for Respironics Oro-nasal than Fischer
Paykel.
Motion reduction while in HFPV breathing compared to that of free breathing,
is an important parameter of this study. Particularly, if such technique is
implemented for use in pencil beam scanning radiotherapy of mobile targets,
which may result in drastic heterogeneous dose distributions (Shirato H. e.)
(Ionascu, 2007) (Bert C. a., 2008) (Jiang, 2006) etc. Although, during this part of
our study we only recorded chest wall motion, we report statistically significant
reduction in ripple magnitude. These results are promising and require further
research. We noticed that most volunteers experienced a drift in motion
amplitude of the chest wall. We believe that such drifts were caused due to the
air leaks around the interface, in addition to the wave pulses losing pressure in
the buccal space/oral cavity as opposed to directly going into the oropharynx for
proper ventilation.
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Duty cycle for respiratory gated radiotherapy is typically 30-50 % for 3DCRT
treatments (Guang-wen, 2011), less than 30% for IMRT treatments (Jiang,
2006) and of course 100 % for non-gated treatments. The ability to deliver the
dose quickly after image verification is critical. Murphy et al (Murphy M. J., 2004)
estimated that if the imaging interval was approximately 2 minutes, then the
percentage of dose that is misdirected by more than 1 mm was in the order of
11 %, whereas 2 % of the dose was misdirected by more than 1.5 mm and less
than 1 % was off target by more than 2 mm. Furthermore, they noticed that if the
imaging interval was reduced by 1 minute, then the mis-targeting was halved.
High frequency percussive ventilation allows us to keep the duty cycle
considerably higher than the current means for IMRT and pencil beam scanning
proton radiotherapy. A median of 93 % duty cycle was observed for 5 mm
threshold band and a median of 52 % for 2 mm. Since no smoothing filters were
applied when collecting the Anzai data (raw data) and the system, like many, is
known to have an inherent noise component (Heinz, 2015) (McNamara, 2008),
we believe that the duty cycle for the 2 mm and 5 mm threshold band could be
slightly higher than reported here. Example of the noise peaks are reported in
(Figure 0-14:).
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Figure 0-14: Sample signal of Amplitude drift & noise from Anzai laser

Additionally, it is believed that leakage around the interface allowed the
volunteers to not be fully ventilated, resulting in the chest wall amplitude drifts
noted above. Consequently, resulting in low duty cycle for both 2 mm and 5 mm
threshold band.
Our last aim for this study was to examine the prolonged time under HFPV
and whether one of the interfaces prolonged percussive time more than the
other. Recalling that each volunteer underwent at least one percussive session
[Figure 0-7:] per interface (number of sessions was left at the discretion of the
volunteer), we recorded a total of Ns=33 (Nv=10), 11 sessions per interface that
were greater than sixty seconds. Statistical differences were noted between the
three interfaces (p< 0.0001). The mean prolonged time for Phillips Respironics
oro-nasal was longer than the other two interfaces. We believe that this was due
the straps around the neck/forehead and the ability of the interface to rest
comfortably around the patients' oral space as indicated in the comment section
of the subjective survey. However, it is important to note that the duty cycle for
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the 5 mm threshold band was lower for Phillips Respironics than the other two
interfaces. We believe that this was due to the indirect path of the percussive
bursts, different from Fischer & Paykel Oracle 452. The Amici TruFit allowed for
similar direct path; however, the lack of straps around the face made it difficult to
keep the interface in place for long periods of time.
1.17 Conclusion
In this part of the study, we showed that the Fischer & Paykel Oracle 452
interface can prolong the percussive sessions when compared to the other two.
Chest-wall motion was well tolerated and drastically reduced using HFPV in
each volunteer evaluated. Average chest wall motion during free breathing and
HFPV was measured at 8.14 mm and 2.52 mm respectively. Even though tumor
motion may or may not correlate well with that of the chest wall, we expect that
the reduction in motion, in addition to prolonged time under HFPV, may translate
to tumor immobilization. As a result, we believe HFPV may provide thoracic
immobilization during radiotherapy, particularly in the SBRT and scanning pencil
beam proton therapy setting.
CHAPTER 4: DOSIMETRIC QUANTIFICATION OF INTERPLAY
EFFECTS OF HFPV FOR PENCIL BEAM SCANNING PROTON AND
GRADIENT EFFECTS FOR PHOTON RADIOTHERAPY:
RETROSPECTIVE PHANTOM STUDY
1.18 Abstract
Purpose: High frequency percussive ventilation (HFPV) is an emerging
technique to reduce respiratory motion. The purpose of this study is to evaluate
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the interplay effects of free vs. HFPV breathing for pencil beam scanning proton
radiotherapy as well as gradient effects for photon radiotherapy.
Methods: Healthy volunteers were previously recruited to undergo free and
HFPV breathing while simultaneously measuring their chest wall respiratory
motion from projecting a laser light on the patients’ skin and measuring its
displacement to the laser sensor. Ten respiratory wave forms obtained from the
sensor were utilized to drive a dynamic thoracic phantom which held Gafchromic
film at iso-center. Each film was irradiated with a proton pencil beam scanning
plan of a known pattern while simultaneously moving with the pre-determined
pattern. Same method was applied for photon films.
Results: Free vs. HFPV curves showed statistically significant differences in
Gamma passing rates. Mean gamma passing rate was 77.03 % (SD: 4.11) and
99.20 % (SD: 0.55) for free- and HFPV breathing patterns respectively. The
number of re-paintings necessary to achieve optimal interplay mitigation was
drastically reduced from 10 to 1 for free vs. HFPV, respectively. HFPV resulted
in consistent Gamma passing rates across several depths of a spread-out Bragg
peak while free-breathing resulted in a significant decrease at the distal edge.
Mean gamma rates for HFPV at 6, 9 and 12 cm depth were: 99.28, 98.24,
96.76% whereas for free-breathing 72.46, 71.58 and 54.21%.
Conclusion: Using HFPV as a thoracic immobilization technique may provide
significant advantages in addressing motion mitigation of proton interplay effects
as well as photon gradient effects.
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Keywords: HFPV, motion reduction, interplay, respiratory motion, pencil beam
scanning proton}
1.19 Introduction
Recent clinical trials in proton radiotherapy have led to promising results
(Siegel, MillerKD, & Jemal, 2015), but motion management of mobile tumors
remains a serious challenge (Allen A, et al., 2012) for both protons and photons.
Although, photon radiotherapy has been the standard of care for thoracic
cancer for decades, the technological advances and clinical trials in proton
radiotherapy have led to promising and effective results (Westover, et al., 2012).
Data shows that proton radiotherapy can spare more healthy tissue, while
maintaining a conformal dose distribution around the target, compared to photon
radiotherapy (Chang, et al., 2016) (Gomez, et al., 2013) (Register, Zhang,
Mohan, & Chang, 2011). The first proton facilities in the United States, utilized
for clinical therapy, was in operation at Loma Linda University Center in
California as well as Harvard University in Boston in the early 1950s. Since then,
therapy proton treatment centers have increased to an astonishing 32 (PTCOG,
2019), with additional centers currently under construction.
Protons are considered to be heavy charged particles which result in minimal
scatter, high cross sections and inversely proportional stopping power. The
resulting effect is that they deposit low entry dose, higher energy at the end of
their range, known as the Bragg peak, and essentially no dose beyond the peak.
These properties result in extensive reduction of integral dose when compared
to photon radiotherapy (Allen A, et al., 2012). The width of the Bragg peak is
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often too narrow for most clinically observed targets in radiotherapy, as a result
its modulation; also known as SOBP (spread out Bragg peak) is often
necessary. Bragg peak modulation can be achieved by either switching beam
energies or by introducing a modulator in the beam path. In either case, the
weighted combination of all the peaks results in a flat dose distribution that is
practical for uniformly treating deep seated targets (Figure 0-5:).
There are two main delivery techniques in proton radiotherapy: passive
scattering proton therapy (PSPT) and pencil beam scanning (PBS). PSPT relies
on primary and secondary scattering material in order to create a 3D conformal
dose distribution in the target, whereas PBS utilizes a sub-centimeter pencil
beam that is scanned across the target one spot at a time. Unlike PBS, PSPT
technique is limited to a predesignated SOBP modulation, therefore not optimal
for mobile targets. However, recent guidelines from PTCOG (Particle Therapy
Co-Operative Group) suggest that PBS has resulted in clinically positive
outcomes when treating thoracic tumors with minimal motion (Chang, et al.,
Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy
for Thoracic Malignancies on Behalf of the PTCOG Thoracic and LYmphoma
Subcommittee, 2017).
Despite the technological advancements which have substantially improved
the beam delivery accuracy, mobility of the target and motion management
remain an important variable that require attention. Target motion is often
represented as two types: stochastic and systematic (Murphy M. J., 2004).
Stochastic motion is random in both time and direction. Systematic motion can
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consist of slow, quasi-static changes in position due to effects such as muscle
fatigue as well as rapid, cyclic changes caused by respiration and heartbeat
(Murphy M. J., 2004). These types of motions lead to target displacement in the
thoracic region that can be as large as 2.47 cm during treatment
(Seppenwoolde, et al., 2002) (Shimizu, et al., 2001). Such discrepancies in
tumor motion have been widely discussed in the literature (Seco, Robertson, &
Trofimov , 2009) (Torshabi, 2013) (Evans, Coolens, & Nioutsikou, Effects of
averaging over motion and the resulting systematic errors in radiation therapy,
2006) (Harada, et al., 2016) (Jakobi, Perrin, Knopf, & Richter, 2018) (Liu, et al.,
2007) (Mutaf, et al., 2011) (Hui, et al., 2008) (Zeng, et al., 2015) (Dasu, Flejmer,
Edvardsson, & Nystrom, 2018), particularly when utilizing PSPT vs PBS
(Langen & Zhu, 2018).
It is reported that 50 % of early-stage and 40 % of locally advanced nonsmall-cell lung carcinoma (NSCLC) move greater than 5

mm in the

superior/inferior direction, respectively (Liu, et al., 2007) (yu, Lin, Balter, Zhang,
& Dong , 2012), thus necessitating some form of motion management. National
guidelines do not recommend treatment of tumors with motion greater than 5
mm (Keall, et al., 2006). Keall et al. (Keall, et al., 2006), recommends against
focal treatment of tumors having greater than 5 mm of motion unless the
radiation facility has no motion management techniques available or the patient
is unable to tolerate them. The dosimetric impact of tumors whose motion is < 5
mm was demonstrated to be minimal by Li et al (Li X. e.), however for motion >5
mm, dose homogeneity and deterioration is significant, therefore, if motion
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mitigation is not available, re-painting the tumor is recommended (Kang, et al.,
2017).
Motion mitigation techniques for proton therapy have been extensively
discussed by Chang et al. (Chang, et al., Consensus Guidelines for
Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies
on Behalf of the PTCOG Thoracic and LYmphoma Subcommittee, 2017). Their
recommendations include the following: motion analysis, 4D dose, robust
optimization evaluation, re-scanning, breath hold, gating and tracking.
The first recommendation requires the analysis of target motion in all
directions, proton beam path, patient anatomy, and the water equivalent
thickness to select beam angles. This is accomplished by the use of iterative
processes,

while

avoiding

critical

structures.

The

downside

of

this

recommendation is that the greatest motion occurs in the superior to inferior
direction (Sarudis, Karlsson-Hauer, Nyman, & Back, 2017). Therefore, orienting
a beam in that direction would be challenging. Additionally, the challenges of
mapping the correct density while the target is moving in and out of the field can
be difficult to accomplish.
Second, 4D dose utilizes all 10 phases of a typical 4DCT scan to obtain an
average dose of each individual phase without considering the time dependence
of the fluence delivery. The disadvantage of this method lies in the uncertainties
of 4DCT which can underestimate tumor volume (Shi, Chen, D'Souza, & Mistry,
2013) (Dou, et al., 2015).
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Third, robust optimization evaluation is simply a method that allows the
optimizer to create a worst-case scenario plan in the event of tumor motion for a
target contoured using 3D or 4D CT. Although, such feature is used in some
clinics, its downside is the decrease of motion sensitivity and certainly may not
accurately predict tumor motion during treatment (Chang, et al., Consensus
Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic
Malignancies on Behalf of the PTCOG Thoracic and LYmphoma Subcommittee,
2017).
Fourth, re-scanning is a widely used method to mitigate motion interplay.
This method allows for the dose to be delivered in several "layers" within a
single daily fraction. It smears the dose by allowing the pencil beam to scan
across the target several times, therefore potentially catching a different phase
of the motion. The downside of this method is the time it takes to switch
between layers, therefore re-scanning is not recommended for proton units with
slow energy switching and has shown to be more sensitive to the starting phase
(Bernatowicz, Lomax, & Knopf, 2013).
Lastly, PTCOG recommends the use of breath hold, gating and tracking as
means to mitigate motion. Breath hold relies on the patients' ability to take the
same volume of air and hold their breath longer than 10 to 20 seconds. This is
often not reliable and only limited to patients who are physiological capable of
breath holds. Gating treatments rely on the beam to turn on/off during a preset
phase (or amplitude). The downside of this method is its low duty cycle and the
accuracy of the predictive filters. Tracking uses either fiducial markers or skin

61
surface to track the tumor, however it can be invasive to the patient and
superficial tracking may or may not correlate well with the tumor itself
(Seppenwoolde, et al., 2002) (Ionascu, 2007).
One technique that has gained less attention as a tool for tumor motion
immobilization is HFPV. HFPV continues to be widely used in mobilization and
clearance of the pulmonary secretions for patients with acute chronic pulmonary
disease (Allan, Osborn, Chung, & Wanek, 2010) (Salim & Martin, 2005). It
provides high frequency bursts of oxygen into the patient's trachea, while
allowing for CO2 to escape through the same interface. The device is an
adaptation of a pneumatic high frequency ventilator in which high flow jets of
gas are delivered to the airways by a flow interrupter called a Phasitron.
Activation of the venturi system within the Phasitron creates bursts of gas at
frequencies of 100 to 400 bursts/minute within a tightly controlled ratio of gas
delivery

and

passive

exhalation.

HFPV

improves

oxygenation

versus

conventional ventilation, with no barotrauma, in patients with acute respiratory
distress syndrome (Gallagher, 1989) (Spapen, 2014). Such technique was
recently used in imaging by (Peguret N. a.-d., 2016) and in radiotherapy by
(Prior J. a., 2016).
On an IRB approved study (IRB# 2017-046), our institution recently recruited
healthy volunteers who underwent HFPV (Sala I. , Maurer, Myziuk, Stevens, &
Guerrero, 2018). The primary purpose of this follow up IRB approved study: is to
investigate the relative interplay effects and the dosimetric impact of free vs.
HFPV motion for PBS and photon radiotherapy. For PBS we aim to investigate:
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the Gamma index Γ, mitigation of interplay effects by the use of re-painting, and
the dosimetric consistency across the SOBP for free vs. HFPV breathing curves.
For photon we aim to investigate: The gradient effects for free vs. HFPV
breathing patterns by analyzing gamma Γ index and hot/cold spots for HFPV
and free breathing patterns relative to and static.
1.20 Methods and Materials
1.20.1 Proton
Chest wall breathing curves from ten volunteers, who previously underwent
free and HFPV (Sala I. , Maurer, Myziuk, Stevens, & Guerrero, 2018), were
imported into our dynamic thorax motion management software (CIRS, Inc
Norfolk, Virginia). A typical signal imported in the phantom's software is shown
in (Figure 0-1:)
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Figure 0-1: A typical chest wall motion signal recorded from volunteer A. First
row represents the Gafchromic films at static, HFPV and free breathing patterns
for volunteer A acquired at a random location in the free and HFPV curve. The
second row represent a differential dose map
The dynamic thorax phantom is comprised of the main body phantom, a
surrogate motion platform and a lung equivalent rod with interchangeable
targets (Figure 0-2:). Both, the rod and the surrogate motion platform, are
connected to an actuator. The surrogate motion platform is designed to simulate
chest wall or diaphragmatic motion, whereas the rod (with target) is designed to
simulate target motion. Both are controlled by the CIRS software. The main
body of the phantom has similar densities to tissue and lung. The rod with
replaceable target sizes is located in the right lung. For the purpose of this
study, all twenty of our motion curves were imported into the surrogate platform,
whereas the rest of the motion axis from the rod/target were set to zero.
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Figure 0-2: CIRS thorax motion phantom Model: 008A
To ensure the accuracy of the actuator motors, quality assurance of the
thoracic phantom was performed prior to the initiation of this study. Two motion
curves were generated, the first curve was Cos(x^4) and the second was Sin(x).
Motion amplitude was verified in mm increments from 1 to 25 mm (peak-to-peak
=50 mm). The physical motion of the rod and the surrogate platform were
measured with a calibrated ruler.
Gafchromic EBT3 film was used for each objective. Gafchromic is designed
to measure absorbed dose of ionizing radiation. The active layer of the film is
sandwiched in between two of the polyester base surfaces. The dynamic range
of the film used was 0.1 to 20 Gy with its optimal being 0.2 Gy to 10 Gy. EPSON
Expression 10000XL flatbed color scanner was utilized to scan each film. To
reduce inconsistencies in lateral scan artifacts (Schoenfeldt, Poppinga, Harder,
Doerner, & PoppeB, 2014) due to Beer-Lambert Law, each (8"x10") film was
placed in the same location on the flatbed scanner. All films were analyzed with
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the steepest saturation color for the dose delivered using FilmQA-Pro software
(Bridgewater, NJ).
IBA Proton Accelerator at Northwestern Medicine Proton Center (IBA, Inc
Louvain-La-Neuve Country Belgium), in Warrenville, Illinois was used to
irradiate all of the films in this study.
For the first aim, we placed Gafchromic film parallel to the surrogate platform
and perpendicular to the pencil beam scanning proton therapy beam. A single
energy (159MeV) Bragg peak plan was generated in RaySearch (RaySearch
Laboratories, Inc. Stockholm, Sweden) with and without a 4 cm range shifter.
Distinct PTV's were created in the plan as indicated in the beams eye view
(BEV) in Figure 0-3:. A total dose of 300 cGy was prescribed. The free and
HFPV breathing curve for volunteer B was irradiated five times. Furthermore,
ten of the breathing curves (free and HFPV) were irradiated once without shifter,
and five of them (free and HFVP) were irradiated with shifter in place. Gamma
analysis was calculated using Eq. (8) with a 3%/3 mm and 10 % threshold (TH)
criteria (Low, Harms, Sasa, & Purdy, 1998), where DD is dose difference (%),
DTA is the distance to agreement (mm), Tol is the dose threshold (%) and d is
the distance to threshold (mm). Additionally, maximum and minimum intensities
relative to the reference image were recorded using Eq (9) to identify hot and
cold spots within the defined ROI (region of interest), where Dr is the reference
dose from static film and Dc is the client dose from either free or HFPV film,
depending on film evaluated.
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Figure 0-3: Example of plan created in RaySearch. Light beige background
represents Gafchromic film. Solid green and striped pink represent PTV 1 and 2.
Each grey circle represents a pencil beam of equal MU. Not to scale
(8)
Γ=

+

Δ=(

%

=

(

−

+

)

(9)

∗

/

(10)

Regarding the re-painting aim, we utilized the free and HFPV breathing
curve from volunteer B. The same single energy Bragg peak plan from the
previous aim with a 4 cm range shifter in place was used with the film positioned
at iso-center. A dose of 300 cGy was delivered in 1, 2, 5, 7, 10, 20 and 50 re-
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paintings. Relative % error, of the same ROI, was recorded for each film using
Eq. (10) with 3%\3 mm and TH=10 criteria.
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+
−
+

(11)

(12)

To further evaluate the effects of motion interplay, we calculated flatness and
symmetry for all films irradiated above (with and without 4 cm shifter). Both
flatness and symmetry were calculated using Eq. (11) and (12) as defined in TG
Report 47 of AAPM were Dmax is the maximum dose, Dmin is the minimum
dose, Dleft is the left side dose and Dright is the right side dose.
Lastly, we explored consistency of Γ passing rates for a spread-out Bragg
peak for five free and five HFPV breathing curves relative to static Figure 0-4.
Three pieces of (8"x10") Gafchromic films were placed at the approximate distal
(12 cm), mid (9 cm) and proximal (6 cm) depths of the SOBP (Figure 0-5:). All
three films were placed on the surrogate platform moving with the same phase
and analyzed with Γ criteria of 3%/3 mm and TH=10 utilizing the same pattern
indicated in Figure 0-3:.
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Figure 0-4: Heterogeneity consistency across SOBP. A, B, and C indicating 6,
9, and 12 cm depth of film placement.
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Statistical analysis was performed for each aim. All analyses performed
utilized a one sample t-Test

Figure 0-5: SOBP and the respective film placement at 6 cm, 9 cm and 12 cm
1.20.2 Photon
Five free and HFPV chest wall breathing curves of volunteers that
previously underwent HFPV were utilized to drive the thoracic motion phantom
that

held

high

resolution

GafChromic

EBT3

film.

Simultaneously,

a

predetermined static MLC (multi leaf collimator) defined photon (6MV) field was
chosen to irradiate each film with a dose of 300 cGy. All films were placed on
the motion platform at 100 cm SSD with 2 cm buildup. The mean peak-to-peak
amplitude of the free and HFPV breathing curves were 19.20 mm (SD: 3.33)
and 2.33 mm (SD: 0.82), respectively. We evaluated the dosimetric effects of
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free and HFPV relative to static by measuring the Gamma Index, as defined by
Low et al, with 3%/2 mm and 10 % threshold criteria. Furthermore, hot and cold
spots, relative to static, for a set ROI (region of interest), were evaluated for
each film.
1.21 Results
1.21.1 Proton
The motion accuracy of the surrogate platform was verified to be within the
reported values of +/-0.1 mm from the vendor with R^2=0.9996 for the Cos(x^4)
Eq. (13) wave and R^2=1.0000 for the Sin(x) wave Eq. (14).
= 1.0018 − 0.007

= 0.9999

(13)

= 0.9996 − 0.002

= 1.0000

(14)

The mean motion (peak-to-peak) of breathing curves imported into CIRS
software was 17.12 mm (SD=4.38) and 2.31 mm (SD=1.10) for free and HFPV,
respectively. For the ten films irradiated without the shifter, the mean Gamma
passing rate for 3%/3 mm and TH=10 criteria was 77.03 % (SD=4.11, lower
95% CI of mean=74.09 %, upper 95 % CI of mean=79.98 % and median=78.21
%) and 99.20 % (SD=0.55, lower 95 % CI of mean=98.81 %, upper 95 % CI of
mean=99.60 % and median=99.15 %) for free and HFPV respectively Figure
0-6. The mean hot spot was +29.67 % and +9.33 % for free and HFPV,
respectively. Likewise, the mean cold spot was -17.67 % and -1.66 % for free
and HFPV, respectively Figure 0-7.
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Figure 0-6: Peak-to-peak phantom motion versus Gamma passing at 3%/3 mm.
Dash circle represents an outlier discussed further

Figure 0-7: Peak-to-peak phantom motion (mm) versus (%) hot and cold spots
for free and HFPV breathing
For the five films irradiated with the 4 cm range shifter, mean Gamma
passing rate for 3%/3 mm and TH=10 criteria was 71.27 % (SD=9.35, lower 95
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% CI of mean=59.66 %, upper 95 % CI of mean=82.88 % and median=73.72 %)
and 99.10 % (SD=1.21, lower 95 % CI of mean=97.59 %, upper 95 % CI of
mean=100.00% and median=99.94 %) for free and HFPV, respectively (Figure
0-6:). The mean hot spot was +24.00 % vs +7.34 % for free and HFPV,
respectively; whereas, the mean cold spot was -20.26 % and -4.65 %. All
statistically significant (p< 0.0001) from set mean of 5 %. Gamma passing rate
was statistically significant from tested mean of 95% (p< 0.00476 for free and p<
0.00163 for HFPV).
Furthermore, the mean Gamma passing rate for 3%/3 mm and TH=10
criteria for volunteer B was 78.92 % (SD=2.12, lower 95 % CI of mean=76.29 %,
upper 95% CI of mean=81.54 % and median=78.68 %) and 99.61% (SD=0.51,
lower 95% CI of mean=98.97 %, upper 95% CI of mean=100.00 % and
median=99.90 %) for free and HFPV, respectively. For the same data set, the
mean hot spot was +29.33 % and +8.67 % for free and HFPV; whereas, the
mean cold spot was -18.00 % and -0.00 % for free and HFPV, respectively. A
one sample t-Test was performed showing statistical significance (< 0.007 and
p< 0.045) for both free and HFPV, respectively. The peak-to-peak amplitude for
volunteer B was 16.42 mm and 1.84 mm for free and HFPV, respectively.
The number of re-paintings to maintain a relatively consistent relative error
(Eq. 10) for free curve was 10, whereas for the HFPV curve was 1. Figure 0-8
shows the number of paintings versus the mean relative error.
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Figure 0-8: Number of re-paintings for free and HFPV vs. relative error (%)
For our next aim we investigated the effects that motion interplay has on
flatness and symmetry. Table 3 shows a distribution of flatness and symmetry
for data measured with and without the 4 cm shifter. A one sample t-Test
resulted in no significant difference from the test mean (5 %) for both static and
HFPV. While showing great statistical significance for free breathing curve.
Technique

Flatness (Ave

Symmetry (Ave %)

%)

W/ Shifter

Static

5.76

2.66

Percussive

3.78

1.40

Free

32.46

20.62
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In-Air

Static

6.97

1.78

Percussive

5.89

2.10

Free

31.50

13.00

Table 3: Flatness and Symmetry for In-Air and Range Shifter
Lastly, we investigated whether motion causes unintended dose
distributions for proximal, mid and distal portion of a potential target when
treated with a spread-out Bragg peak, because the most distal end of a target
would only “see” the first peak (identified as 4 in Figure 0-9), however the
proximal end would “see” all. The dose distribution can therefore be distorted
when the target is mobile.

Figure 0-9: SOBP Consistency
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Γ passing rates with criteria 3%/3 mm, 2%/3mm, 1%/1mm and
TH=10 were used to analyze each film for HFPV, free and static. These results
are represented in Figure 0-10 and Table 4.

Figure 0-10: Gamma passing rate for all films relative to their respective static
films. a) HFPV breathing b) Free Breathing
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HFPV Depths
3%/3mm

1

2

3

4

5

Average

SD

6cm
9cm
12cm

99.9%
98.9%
96.7%

98.7%
99.0%
99.0%

97.2%
96.7%
96.3%

98.7%
97.6%
95.2%

97.0%
99.0%
96.7%

98.3%
98.2%
96.8%

1.2%
1.0%
1.4%

Free Depths
3%/3mm

1

2

3

4

5

Average

SD

6cm
9cm
12cm

79.4%
83.0%
69.4%

67.4%
61.6%
51.4%

65.5%
76.8%
54.6%

76.4%
67.7%
48.7%

73.6%
68.8%
47.0%

72.5%
71.6%
54.2%

5.9%
8.4%
8.9%

HFPV Depths
2%/2mm

1

2

3

4

5

Average

SD

6cm
9cm
12cm

96.4%
96.2%
94.2%

97.2%
96.1%
96.2%

95.1%
95.6%
94.1%

96.2%
96.1%
94.4%

96.12%
95.1%
94.2%

96.2%
95.8%
94.6%

0.7%
0.5%
0.9%

Free Depths
2%/2mm

1

2

3

4

5

Average

SD

6cm
9cm
12cm

70.2%
78.0%
60.1%

66.1%
58.2%
48.2%

60.0%
71.2%
50.0%

72.1%
62.1%
44.2%

69.2%
64.1%
43.3%

67.5%
66.7%
49.2%

4.7%
7.9%
6.7%

HFPV Depths
1%/1mm

1

2

3

4

5

Average

SD

6cm
9cm
12cm

92.2%
90.1%
91.0%

92.1%
90.0%
91.1%

90.0%
91.0%
90.1%

90.2%
90.4%
90.1%

91.0%
90.6%
89.2%

91.1%
90.4%
90.3%

1.0%
0.4%
0.8%

Free Depths
1%/1mm

1

2

3

4

5

Average

SD

6cm
9cm
12cm

66.1%
70.0%
54.0%

60.0%
50.0%
41.4%

59.2%
64.6%
46.7%

67.2%
57.2%
40.4%

61.1%
60.2%
38.4%

62.7%
60.4%
44.2%

3.7%
7.6%
6.3%

Table 4: Gamma passing rates for SOBP heterogeneity 3%/3mm, 2%/2mm and
1%/1mm
1.21.2 Photon
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All films were scanned using EPSON 1000CL scanner and analyzed with
FilmQA Pro (Ashland Inc, Bridgewater, NJ) film software. The average Gamma
Index for free breathing vs. HFPV was 79.29 % (SD: 4.65) and 99.70 %
(SD:0.35) respectively Figure 0-11 . The median cold spots for HFPV was -2.86
% and -20.00 % for free breathing. Similarly, the median hot spots for HFPV
was 17.14 % and 5.71 % for free breathing.

Figure 0-11: Gamma Passing Rates for Photon Gradient Effects
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Figure 0-12: Hot and Cold Spots for Photon Beam Gradient Effects
A typical gradient effect of the relative dose difference on the GAFChromic film
is denoted in Figure 0-13.

Figure 0-13: Typical Gradient Effect for GAFChromic photon test
1.22 Discussion
1.22.1 Proton
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The results found in this study validate the importance of motion
management in radiotherapy, particularly for PBS radiotherapy. HFPV provides
significant dosimetric advantages relative to free breathing. This is well
supported by Figure 0-1:, which shows static, HFPV and free breathing for two
randomly selected curves.
EBT Gafchromic film was selected for this study due to its high spatial
resolution of < 25µm. Reference dosimetry performed by (Girard, Hugo, &
LacroixF, 2012) has shown considerable errors in film response of the active
layer due to the influence of humidity, temperature, and non-catalytic
development which can introduce error response as high as 2 % (1-sigma)
(Girard, Hugo, & LacroixF, 2012). Therefore, in this study, we ensured that all
films were kept in the same environment. Additionally, EBT film has shown to
under respond in the presence of proton spread out Bragg Peak (Fiorini, et al.,
2014) and discrepancies (up to 10 %) in dose have been reported at depth due
to the uncertainties of the processor (yeo, Teran, Ghebremedhin, Johnson, &
Patyal, 2015), thus all films processed in this study were placed in the same
location on the EPSON scanner.
While not investigated in this study, the direction of motion parallel to the
pencil beam scanning may yield different results (Dowdell, Grassberger, Sharp,
& Paganetti, 2013) (Lambert, Suchowerska, McKenzie, & Jackson, 2005).
Additionally, it is assumed that the chest wall motion curves obtained from each
volunteer are similar to that of a typical thoracic tumor.
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It was observed that the phase and amplitude for free and HFPV breathing
curves differed widely among all volunteers. Although we elected to irradiate
one film per respiratory curve, at a random phase, it is important to note that
other respiratory phase locations may yield different results. Such dosimetric
variability could be even more significant for large breathing amplitudes. To
estimate the dosimetric outcome of dose delivery at a random respiratory phase,
we irradiated the free and HFPV breathing curves of volunteer B five times. The
free breathing curves resulted in a broader range (SD=2.12) that trended toward
statistical significance, contrary to the narrow range of HFPV (SD=0.51). This
result is particularly important for proton stereotactic body radiotherapy (SBRT)
where the number of fractions delivered is limited (often < 5), potentially
resulting in drastic under- or over-dosage. On the other hand, PBS with HFPV
resulted in high conformity and appears to be unaffected by the difference in
intra-fractional starting phase variably. Therefore, HFPV does not appear to
possess limitations that other motion mitigation techniques exhibit.
Furthermore, we explored if HFPV motion mitigation technique would result
in higher Gamma passing rates and under- or over-dosage. It is evident that
HFPV results in significantly lower percent differences when compared to static
(Figure 0-6:). Similarly, the large range of Gamma and hot/cold spots for the
same free breathing curve is significant and further reinforces the need for
motion management. We do believe that motion reduction by HFPV can provide
satisfactory tumor motion control without requiring any other mitigation
strategies or algorithms previously mentioned by Chang et al. (Chang, et al.,
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Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy
for Thoracic Malignancies on Behalf of the PTCOG Thoracic and LYmphoma
Subcommittee, 2017). One breathing curve circled in Figure 0-7 was an outlier.
This particular volunteer was a non-diaphragmatic breather resulting in almost
the same peak-to-peak chest wall motion for both free and HFPV.
Additionally, several studies have been performed on the effects of spot size
broadening due to the use of range shifters (Shen, et al., 2015) and in this study
we explored the Gamma passing rate for free vs. HFPV curves with and without
a 4 cm range shifter. Although, the broadening of dose smearing was more
evident for the free breathing curves, no statistical difference was observed.
Re-painting has been extensively discussed in literature as a technique to
mitigate motion artifacts, although a single Bragg peak was used, our data is
consistent with (Seco, Robertson, & Trofimov , 2009). The suggested number of
re-paintings per field to obtain a relative error below 5 % is 10 and 1 for free and
HFPV, respectively. The minimum relative error for free breathing was 4.46 %
and 4.21 % for HFPV. We attribute this to the energy dependence of the film (<5
%), its sensitivity (< 5%), uniformity (< 3 %) and EPSON scanner. Nonetheless,
the drastic reduction in repainting from free breathing to HFPV is significant and
enforces the positive impact of HFPV.
For our last aim, we explored the consistency of Gamma index for three films
placed at three different depths of the SOBP (Figure 0-5:). We elected to have
all of them move with the same phase in order to eliminate any errors that could
have been introduced from the phase differences (Bernatowicz, Lomax, &
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Knopf, 2013). It is evident from the results that the Gamma passing rates for the
proximal, mid and distal end of a typical target can be different depending on the
motion amplitude, however HFPV resulted in uniform Gamma, different from
free breathing (Table 4) and (Figure 0-10). This can be explained from the way
each Bragg peak is delivered. The distal end of a typical moving target can
potentially only “see” one peak whereas the proximal end will “see” all of them
Figure 0-9.
We previously noted that approximately 50% of the early stage tumors move
> 0.5 cm and about 40% for locally advanced NSCLC required some type of
motion mitigation technique. However, those techniques had significant
limitations and uncertainties that may not apply to some patients, therefore we
believe that HFPV can be superior in consistently addressing all tumor stages
and motion amplitudes.
1.22.2 Photon
As previously noted, photon beams are not delivered with a pencil beam
technique like proton therapy, therefore the outcome of gradient and interplay
effects can be different. In this study we only measured the gradient effects
(MLC Static) and as anticipated the edges of the field are drastically either overor under-dosed, therefore motion mitigation is greatly recommended and the
application of large enough margins, that would encompass the entire trajectory
of a target, is necessary. HFPV can drastically reduce motion and consequently
have acceptable Gamma passing rates for photon radiotherapy.
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1.23 Conclusion
High frequency percussive ventilation can result in significant dosimetric
advantages for PBS radiotherapy. It drastically mitigates the interplay effects
and significantly lowers the hot/cold spots relative to free breathing. Additionally,
it allows for highly homogeneous and consistent dose distribution across several
depths. HFPV may be able to address and treat all motion amplitudes and
potentially lead to revenue increase while consistently maintaining high target
conformity and OAR sparing.
CHAPTER 5: DETERMINATION OF DIRECT TUMOR AND DIAPHRAGM
MOTION WITH HFPV: PROSPECTIVE STUDY
1.24 Determination of Direct Tumor Motion using Fluoroscopy
1.24.1 Abstract
Purpose: The purpose of this prospective study is to investigate HFPV as a
respiratory motion technique to directly immobilize thoracic tumors.
Methods: A total of 105 lung patients with conspicuous tumor were
prospectively screened to enroll in an IRB approved study. Only 27 had tumors
that moved greater than 10 mm as part of the inclusion criteria for the study.
Seventeen of them declined participation and 9 were excluded due to their age
and COPD FEV1 scores < 50% as indicated in the exclusion criteria of the
protocol. Only one patient accepted and underwent fluoroscopy imaging while
in free and HFPV breathing. Patient was setup supine with arms above her head
in the treatment couch of the Elekta (Elekta, Stockholm, Sweden) Linear
Accelerator. The kV arms of the Linear Accelerators were used to obtain 1D
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images every 5.5 seconds. A total of 147 1D frames in the AP direction were
obtained during HFPV breathing mode and 92 in free breathing. Each frame
was acquired continuously with gantry at 270 degrees and kV=120, mA=25,
ms=40 and SFOV (Small Field of View). The size of the images was
512x512x16bit with a Horizontal and Vertical resolution of 0.518 mm/pixel. Two
different points within the tumor were traced along each fluoroscopy frame for
both free and HFPV breathing.
Results: Patient tolerated the procedure well. She had previous COPD history,
therefore total peak pressure applied was 12cmH2O. The mean peak-to-peak
motion of the tumor during free breathing was 6.20 cm, lower than that recorded
during 4DCT, while peak-to-peak motion of the tumor during HFPV was 2.675
cm, resulting in 57% reduction of motion.
Conclusions: This is the first study to ever report direct tumor motion with
HFPV. It is evident that despite the lower peak pressure that the patient
tolerated, motion was significantly reduced, making HFPV a viable technique for
respiratory motion.
1.24.2 Introduction
High frequency percussive ventilation (HFPV) is a novel immobilization
technique that has gained little attention in radiotherapy. It utilizes high
frequency low tidal volume ventilation to produce endotracheal percussion
(Salim A. a., 2005) (Allan, Osborn, Chung, & Wanek, 2010). It deliverers 100 to
400 bursts of oxygen per minute into the patients’ trachea while simultaneously
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allowing for passive O2/CO2 exchange. HFPV improves oxygenation versus
conventional ventilation, with no barotrauma, in patients with acute respiratory
distress syndrome (Spapen, 2014) (Gallagher, 1989).
Previously, in an IRB approved study (IRB# 2017-046), we evaluated HFPV
for chest wall motion immobilization (Sala I. , Maurer, Nair, & Guerrero, 2019).
We found volunteers tolerated the HFPV for varying lengths of time – from a few
to tens of minutes. In that study, we reported significant reduction in chest wall
motion after initiation of percussive ventilation (mean: > 60%) as well as high
duty cycle (mean: > 80%).
Recently, high frequency percussive ventilation (HFPV) was reported for
immobilization of thoracic tumors for imaging (Prior J. e., 2016) and stereotactic
body radiotherapy (SBRT) (Peguret N. e., 2016). In Peguret’s SBRT study,
thoracic tumor respiratory motion was inferred from changes in the chest
diameter measured by an Anzai respiratory belt (ANZAI Medical Co, Tokyo,
Japan). There were patients who could not tolerate percussive ventilation
assisted breath-holds for greater than 10 to 15 seconds. That preliminary study
provided no direct evidence of tumor motion reduction. Filling this gap in
knowledge is an important consideration before moving HFPV into clinical
practice for tumor immobilization.
In this first-in-man clinical case study, we combined HFPV and fluoroscopy
to directly visualize and quantify tumor motion.
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Figure 0-1: Cohort II Patient Tumor Location
1.24.3 Methods and Material
1.24.3.1
atient Selection

P

Any patient with conspicuous (visible on projection x-ray, e.g. CT scout AP
projection) lung tumors that exhibited ≥ 10 mm motion on their standard of care
treatment planning 4DCT was recruited for this study. Between December 2018
and July 2019, we screened a total of 105 lung patients. Of which 27 had
conspicuous tumors that moved >10 mm. Of the twenty-seven, seven had
COPD FEV1 (Forced Expiratory Volume) score <50 percentile which
automatically excluded them from the study. One was under the age of 18,
which also excluded them from the study. Eighteen declined for personal
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reasons. Only one patient accepted and underwent fluoroscopy with HFPV. The
patient was a 69-year-old female with Stage IB (cT2a, cN0, cM0)
adenocarcinoma of the LLL (left lower lobe) with lepidic and acinar growth
pattern Figure 0-1.
1.24.3.2
rocedural Workflow

P

The patient was connected to the intrapulmonary percussive ventilation (IPV2C) device (Percussionaire Corp., Sagle, Idaho) through the Phasitron and the
Fischer & Paykel Oracle 452 CPAP (Fischer and Paykel Healthcare, Auckland,
New Zealand) interface. The patient was then transferred to the treatment room
where she was setup supine using her three-point isocenter tattoos with both
arms above her head. We acquired two sets of consecutive fluoroscopy frames
during multiple breathing cycles. One set was acquired while the patient was
freely breathing and the other approximately 10 seconds post HFPV initiation.
The settings of the Percussionaire IPV-2C (pressure, frequency, CPAP,
inspiration time) were set by a certified respiratory therapist, but at the direction
and comfort of the patient.
All fluoroscopy images were acquired in the AP (Anterior Posterior) direction
with the gantry positioned at 270 degrees. Images were acquired with kV=120,
mA=25, ms=40 and SFOV (Small Field of View) and a frame rate of 5.5
frames/second. The size of the images was 512x512x16bit with a Horizontal
and Vertical resolution of 0.518 mm/pixel.
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Two points were selected in the target and traced along each fluoroscopy
frame as indicated in Figure 0-3.
Prior to initiation of Cohort II quality assurance was performed on the
fluoroscopy unit to ensure that it would identify tumor location correctly. A
predetermined motion curve was imported into the CIRS motion phantom
(CIRS, Inc Norfolk, Virginia) with a BB (high density material) attached at the
end of the mobile rod. The phantom underwent fluoroscopy imaging while in
motion Figure 0-2 using the kV (motionview) arms of the Elekta Linear
Accelerator (Elekta, Inc, Stockholm, Sweden). A python-based algorithm was
designed to trace the BB across all of the frames acquired.

Figure 0-2: Motion Phantom with BB at the end of the mobile rod (Blue arrow)
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Figure 0-3: Point Motion Tracing Along Fluoroscopy Frames
1.24.3.3
tudy Oversight

S

Patient was enrolled in the study following IRB approval (#2017_046) and
verification of the inclusion criteria. Informed consent and authorization
document specific to the study were provided to the patient. The patient was
informed about the rationale of the study, logistics, risks and how the data would
be used.
1.24.4 Results
The pre-determined signal imported into the motion phantom was within
0.2 mm accuracy to the traced signal from the fluoroscopic images obtained.
The red line represents the expected target motion and the black line represents
the BB motion acquired from each fluoroscopy frame.
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Figure 0-4: Quality Assurance of Fluoroscopy Imaging. Red indicating the
imported pattern and black indicating the bb tracing along each fluoro imaging
obtained.
A total of 92 fluoroscopy frames were acquired while the patient was in
free breathing and 147 in HFPV. Patient had prior history of COPD and was
unable to tolerate a peak pressure higher than 12 cmH2O, whereas the healthy
volunteers in Cohort I were between 20-22 cmH2O. A few of the fluoroscopy
frames with contours of the tumor visualized tumor motion during free- and
HFPV breathing is shown in Figure 0-5.
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Figure 0-5: Direct tumor motion measurement with HFPV
The two points that were traced along each frame are represented in Figure 0-6

Figure 0-6: Direct Tumor Motion Graph. Point 1 and 2 represent two different
points within the tumor
The mean peak-to-peak motion for free breathing for both points was 6.2
mm (slightly lower than 10 mm measured during 4DCT). The mean peak-topeak motion for HFPV breathing for both points was 2.7 mm. Therefore, the
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mean reduction in tumor motion while in HFPV, for both selected points, was at
57%.

Although the correlation of tumor motion as it relates to chest-wall

motion was not investigated for this patient, due to the length of time and
discomfort that patient was on the table, the relative % reduction is comparable
to the results of Cohort I.
1.24.5 Discussion
Target respiratory motion and control continues to be of importance in
radiotherapy. More recently, in a landmark study by Cuculich et al (Cuculich, et
al., 2017) in the New England Journal treated five patients, with a single dose of
25 Gray to the area of heart responsible for generating ventricular tachycardia.
6 weeks following treatment, patients were observed and found to have a 99.9%
decrease in the frequency of ventricular tachycardia episodes. They detected
6,577 total episodes during 3 months before therapy, compared to only 4
episodes for 46 patient-months following SBRT and a 6-week wash-out period.
Despite the good clinical outcomes of the study, no respiratory management
techniques were applied, and this remains a concern.
Providing consistent and direct tumor motion control is critical in
escalating radiation doses, while maintaining good sparing of the healthy tissue.
In this study we show direct tumor motion management that is consistent and
maintained for longer periods of time than a typical breath-hold. Although the
patients’ last reported FEV1 score was in the normal range (>50 %), the patient
had previous history of COPD which might have hampered our ability to
maintain a pressure of 20 cmH2O, like that seen in the volunteer cohort.
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However, even with the low peak pressure of 12 cmH2O motion was drastically
reduced relative to patients free breathing.
Additionally, tumor motion recorded during the 4DCT simulation was
about 11 mm, however free breathing motion during fluoroscopy was
approximately 6.2 mm. Although, the motion was slightly different, we attribute
this to the 4x10Gy fractions that the patient had already received prior to her
fluoroscopy study. We believe that tumor size/motion might have changed from
what was initially recorded in 4DCT.
In this study we did not evaluate prolonged HFPV times that the patient
could’ve tolerated, but rather acquired several hundred fluoroscopic frames that
would allow us to calculate direct tumor motion. Patient was however
comfortable with the device and the length of time that she was in HFPV (<5
mins). We were unable to setup the external Anzai laser system on the patient’s
chest wall due to the setup time and her discomfort on the hard table top, but we
aim to do so for subsequent patients.
To our knowledge, this is the first study to ever show direct tumor motion
using such a novel technique for radiotherapy. Its drastic reduction of tumor
motion, prolonged time, and other parameters measured in the Cohort I, make
HFPV

a

promising

technique

for

respiratory

motion

management

in

radiotherapy, particularly for high risk cases like SBRT and cardiac arrythmias
like the study by Cuculich et al (Cuculich, et al., 2017).
1.24.6 Conclusions
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HFPV is a viable and novel technique that can be used for direct tumor
immobilization. In this first ever study, we showed significant tumor reduction
relative to free breathing.
1.25 Determination of Direct Diaphragm Motion using MRI
1.25.1 Introduction
Magnetic Resonance Imaging (MRI) in the thorax is complicated by the
low proton density of lung parenchyma (Mulkern, et al., 2014) )and motion due
to breathing or the beating heart (Schultz, Alfidi, Nelson, Kopiwoda, & Clampitt,
1984). Motion causes image artifacts that appear as blurring, ghosting or image
harmonics, and misregistration. Images corrupted by motion are often
uninterpretable. Respiratory motion can be suspended for < 30 seconds by
breath holding in healthy cooperative patients. This time can by lengthened
using supplemental oxygen and hyperventilation by up to 40%. The effect of
respiratory motion is illustrated in Figure 0-11, where a thoracic MRI image
volume was acquired while breathing versus during a breath hold. The yellow
arrows demonstrate the motion of the diaphragm and consequently the
elongation of the heart.
The MRI signal-to-noise ratio is proportional to the voxel size and to the
square root of the number of averaged measurements. High spatial resolution
therefore requires long data acquisitions; up to 10 mins of data acquisition. For
these longer acquisitions, respiratory and cardiac gating may be employed.
However, dual gating introduces a lower acquisition duty cycle prolonging the
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total acquisition times. A method to reliably suspend respiratory motion for ≥ 10
minutes is needed.
MRI has high soft-tissue contrast allowing the differentiation of malignant
versus benign processes, such as tumor and atelectasis. This has the potential
for more accurate targeting of the malignancy while sparing normal tissue has
lead the interest in using MRI for radiation therapy treatment planning simulation
(Schmidt & Payne, 2015) and for image-guided delivery (Raaymakers, et al.,
2017) (Lagendijk, et al., 2014) .
Combined MRI and radiotherapy machines are being introduced to
provided image-guidance during treatment delivery. The radiation oncology
department currently has a 3T Philips Ingenia MR simulator. An Elekta Unity
MR-Linac utilizing a Philips 1.5 Tesla MRI machine is scheduled for installation
late-2019 at Beaumont Hospital, Royal Oak. Motion remains an issue both for
thoracic MRI imaging and for radiotherapy delivery for MR-Linac machines. The
motivation behind this study is to use HFPV as a method to reproducibly
suspend respiratory motion during MR imaging and directly measure diagraph
motion.
1.25.2 Methods and Materials
One volunteer was recruited to prospectively undergo MRI imaging while
in HFPV, free and breath-hold for two consecutive days. The Fischer and Paykel
mask, that was used during Cohort I, was utilized for this study. Due to the
ferromagnetic material in the Percussionaire unit, the custom designed 20-foot
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tubing, described in Figure 0-5 D), was utilized to connect the Phasitron (MR
compatible) to the Percussionator which was located by the treatment console,
outside of the MR field (Figure 0-7). The Sentec or the Anzai laser system were
not utilized for this study due to their MR incompatibility. The volunteer was in
HFPV during the entire imaging acquisition process (> 25 minutes).

Figure 0-7: MRI Setup with HFPV
MRI data was acquired on the Department of Radiation Oncology’s 3T
Philips Ingenia MR simulator, equipped with 32 channel torso coils. The subject
was setup in a supine position, head first, on the flat table top, with the torso coil
placed on the coil bridge (Figure 0-7). We acquired three, 3D T1 TFE weighted
imaging data with fat suppression radially using Enhanced T1 High Resolution
Isotropic Volume Excitation (e-THRIVE), performed using breath-hold, freebreathing, and HFPV acquisitions.
The pressure and frequency at the end of the 15 and 20- feet long tubing
was tested prior to initiation of this study. Each tube was connected individually
to a custom designed Phasitron which held an inflated balloon. The Anzai laser

97
system was projected on the balloon. Frequency and pressure changes were
incrementally changed following the same procedure as described in Section
1.28.1.
1.25.3 Results
The 15 and 20-feet tubing decreased the balloon volume much more
rapidly (Figure 0-8) than the standard 4-foot tubing clinically used when only the
frequency dial was changed (from highest to lowest frequency). However, this
was only noticed towards the end of the dialing range (8-12).

Figure 0-8: Changes in Frequency for 4, 15 and 20ft Phasitron tubing.
Similarly, as the pressure decreased, the balloon was drastically
affected. The 4-foot tubing provided slightly higher pressure at the balloon than
the 15ft or the 20ft, however a reversal was noticed towards the 6-11 dial range.
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Figure 0-9: Changes in Pressure for 4, 15 and 20ft Phasitron tubing
Incremental changes for frequency and pressure resulted in similar outcomes
for the clinically sued dials (3-9).

Figure 0-10: Changes in Frequency and Pressure for 4, 15 and 20ft Phasitron
tubing
The volunteer was setup in the MRI unit with arms above his head and
20-foot tubing. Like the other cohorts, a peak pressure between 19-20cmH2O
and frequency of approximately 300-350 bursts/min were achieved without any
significant loses in ventilation.
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For day 1, diaphragm peak-to peak motion relative to breath hold was
5.25 cm for free- breathing and 0.18 for HFPV. Similarly, for day 2, diaphragm
motion relative to breath-hold was 5.13 cm for free-breathing and 0.12 cm for
HFPV.
a

b

Figure 0-11: MRI with HFPV a) indicates images acquired in day 1 and b) those
acquired in day 2. Yellow arrows indicate the extent of motion for free, breath
hold and HFPV breathing.

1.25.4 Discussion
It is evident from the results that within the clinical operating limits
between 3 to 8, the Percussionator can deliver adequate pressure and
frequency for both 15- and 20-feet tubing. Similarly, the peak pressure and
frequency achieved during the prospective volunteer study was easily achieved
and matched the Cohort I and II parameters of about 20cmH2O and 350
bursts/min frequency.
The volunteer was able to tolerate the entire image acquisition process of
>25 minutes without interruption of HFPV. The drastic reduction in diaphragm
motion is further indication that HFPV is a novel technique in reducing motion for
long periods of time (>25 mins) and comparable to that of breath-hold. This is
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significant when compared to conventional kV imaging because MRI has high
soft tissue contrast. Additionally, HFPV greatly reduced image artifacts that are
caused due to motion. These artifacts are prominent around the heart and liver
in Figure 0-11.
1.25.5 Conclusions
We have demonstrated that HFPV can be utilized in an MRI setting for long
periods of time (>25 mins) and drastically reduces diaphragm motion (>90%) as
well as motion artifacts noticed during imaging.
CHAPTER 6: A RETROSPECTIVE PLAN STUDY OF THE DOSIMETRIC
IMPACT OF HFPV
1.25.6 Abstract
Purpose: The purpose of this retrospective study is to investigate and quantify:
1) PTV volume reduction and 2) OAR sparing for HFPV as a tumor
immobilization technique.
Methods: In an IRB approved study we previously recruited volunteers to
undergo HFPV. Their chest wall motion was recorded using a laser system that
was projected 10 cm inferior to the xyphoid process. A total of 3 HFPV and 3
free-breathing chest wall motion curves were imported into a motion lung
phantom. The phantom underwent 4DCT while the 2cm target imbedded inside
the phantom moved as determined by each imported curve. Varian RPM was
utilized to bin each CT slice into 10 phases (10-100 %). An average and MIP
were created from each 4DCT. The target was contoured on the MIP and the
OARs on the average. A uniform 5 mm margin was applied to all ITVs. OARs
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and target were contoured on each scan by qualified professionals. A total of 6
(3 free and 3 HFPV) RapidArc treatment plans were created using 10FFF, with
two partial beams and 30-degree collimator rotation. Each plan was designed to
deliver 50 Gy in 5 fractions.
Results: The PTV volume was reduced by > 7cc for HFPV. V5 and V20 were
also scientifically reduced by >5 Gy and >3 Gy, respectively. Similarly mean
heart dose was reduced by as much as 3.56 Gy
Conclusion: We have shown that HFPV dosimetry is greatly improved relative
to free-breathing. Relative to free breathing, HFPV plans were superior in
reducing V20, V5, Heart doses as well as PTV volumes.
1.25.7 Introduction
The goal of radiotherapy planning is the accurate delivery of radiation to
the target while limiting the dose to nearby healthy tissues. Improvements in
radiation delivery techniques (Armstrong, 1993) enable clinicians to achieve
these

goals.

The

International

Commission

on

Radiation

Units

and

measurements (ICRU) Report 50 (ICRU 50, 1993) and the Supplement Report
62 (ICRU 60, 1999) describe the current recommendation for incorporation of
tumor motion into radiation therapy planning. In the thorax, targeting is
complicated by respiratory motion, which can cause tumor displacements as
large as 2 cm during treatment (Seppenwoolde, et al., 2002) (Shimizu, et al.,
2001) (Seppenwoolde Y. e., 0094-2405). Accurate targeting is critical,
particularly for SBRT, in which high doses of radiation are delivered in just 1 to 5
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fractions. The American Association of Physicists in Medicine (AAPM) Task
Group 76a report on the management of respiratory motion in radiation
oncology (Keall, et al., 2006), recommends margins around the treatment target
be sufficient to ensure coverage of the target.
In a landmark SBRT trial for early stage inoperable lung cancer,
Timmerman, et al. used planning target volume (PTV) expansions from the
gross tumor volume (GTV) of up to 5 mm in the axial dimension and 10 mm in
the cranial-caudal (CC) direction (Timmerman, et al., 2010). This relatively large
PTV expansion in the CC direction results in a larger volume of healthy tissue
being irradiated. Four-dimensional computed tomography (4DCT) provides a
snapshot of respiratory-induced tumor motion and is used to individualize the
internal target volume (ITV) [10], yielding smaller treatment margins than
fluoroscopy. As 4DCT scanning and image-guided radiotherapy (IGRT) became
more readily available, recent studies have reduced the PTV margins to a 5 mm
uniform expansion around an ITV that accounts for respiratory motion (Liang) (Li
X. e.) (Kilburn, 2016).
In the SABR-COMET trial there was a 4.5% death rate due to radiation
pneumonitis, GI bleed, and lung abscess. Similarly, In RTOG 0617, increasing
the dose from 60 to 74 Gy killed more patients than it saved. Therefore,
reducing margins while still maintaining high therapeutic doses is critical. In this
retrospective simulated study we evaluate whether HFPV motion has an impact
on 1) PTV margin reduction (volume), 2) spearing of healthy organs.
1.25.8 Methods and Material
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In this study we randomly selected a total of six breathing curves from
Cohort I data, three HFPV and three free breathing. Their peak to peak
amplitude for free-breathing was 22.8 mm, 22.8 mm and 16.415 mm and 3.2
mm, 2. mm and 1.8 mm for HFPV. Each pattern was imported into the CIRS
lung phantom. The RPM (Real Time Position Management by Varian Medical
Systems, Palo Alto, California) cube with the fluorescence reflectors was
position on the platform and the infrared camera projected on (Figure 0-1).

Figure 0-1: 4DCT of Lung Thoracic Motion Phantom using RPM
A 4DCT of the body of the phantom, with a 2 cm target in the mobile rod,
was acquired for each of the breathing curves utilizing a 16 slice GE scanner
(GE Healthcare, Chicago, IL). All scans were performed using 1.25 mm slice
thickness and 120kVp. GE Advantage Sim MD was utilized to bin each slice into
the appropriate phase bin. Average and MIP (Maximum Intensity Projection)
reconstructions were automatically performed for each of the six scans. The 2
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cm target in the mobile rod was contoured on the MIP, however the
computerized treatment plan was done on the average CT.
A total of 6 plans were designed. Three with the average 4DCT acquired
from free breathing patterns and three with the average 4DCT acquired from
HFPV breathing patterns. We utilized a 10FFF (Flattening Filter Free) beam with
HDMLC RapidArc for creating all computerized plans using Eclipse (Varian
Medical Systems, Palo Alto, CA) treatment software. Jaws were conformed to
the target with 0.5 cm uniform margin. Two partial arcs were utilized, one going
clockwise and the other counter-clockwise (345 to 180 degrees). The collimator
was rotated at 30 and 330 respectively for each arc. A standard Flattening Filter
Free dose rate of 2400MU/min was used. Heterogeneity was turned on for all
plans.
Target was contoured by a board-certified radiation oncologist, whereas
the OARs by a board-certified radiation physicist. A standard SBRT prescription
of 50 Gy in 5 fractions was used. All plans were normalized to deliver at least
95% of the dose to 100% of the target. OARs contoured: Chest-wall, Heart, L/R
Lung, Lungs-PTV, Spinal Cord, Spinal Cord+5 mm, Spinal Cord +3 mm. The
PTV was identified by contouring the ITV (target along each of the 10 phases
identified) plus a uniform 5 mm margin.
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The acceptable plan criteria were based on RTOG 0813 protocol for 50 Gy in 5
fractions as noted in Table 5: RTOG 0813 Criteria for 50Gy in 5 fractions Table
5.

Volume
Heart:
< 15cc
Spinal Cord <0.25 cc
< 0.5 cc
Lung-GTV <1500 cc
< 1000 cc
Skin
< 10 cc

Dose Max Point
> 32 Gy < 52.5 Gy
> 22.5 Gy < 30 Gy
> 13.5 Gy
> 12.5 Gy
> 13.5 Gy
> 30 Gy

Table 5: RTOG 0813 Criteria for 50Gy in 5 fractions
1.25.9 Results
A summary of the results are represented in Table 6. To be noted that
the average PTV volume defined during free breathing was 12.067cc vs. 4.7cc.
Similarly, V20 and V5 of the lung was drastically reduced from a mean of 5.44
Gy (Range: 3.3 -7.97Gy) to 1.94 Gy (Range: 1.68 – 2.46 Gy) for V20 and 16.49
Gy (Range: 14.3 – 20.24 Gy) to 10.74 Gy (Range: 8.84 – 13.31 Gy), for V5 for
Free vs. HFPV breathing respectively.
Maximum hot spot distribution was statistically non-significant between
the two breathing patterns. The 15cc criteria for the heart dose was significantly
different from 16.64 Gy (Free Breathing) to 13.08 Gy (HFPV).
An iso-dose color wash sample of the plans is represented in Figure
0-2. It is evident that the drastic motion reduction allows for a conformal dose

106
distribution

around

the

2

cm

target.
TARGET

OARs
Lung - PTV

Free Breathing 1
Free Breathing 2
Free Breathing 3

2.296
1.45
0.35

1.089
0.539
-

110.2
108.6
110.4

5.06
3.302
7.97

20.24
14.94
14.3

6.854
6.29
6.69

5.6
5.93
6.44

Heart
<15cc
receives
>32Gy
(Gy)
18.22
15.39
16.31

HFPV Breathing 1
HFPV Breathing 2
HFPV Breathing 3

0.6153
0.66
0.58

0.2637
0.27
0.18

107.4 1.6864
105.9 1.68
107.1 2.46

8.843
10.06
13.31

5.77
5.62
5.74

6.37
5.22
5.43

13.84
13.34
12.06

5
4.4
4.7

54.31
53.89
55.65

Δ1
Δ2
Δ3

1.6807
0.79
-0.23

0.8253
0.269
#VALUE!

2.8
2.7
3.3

3.3736
1.622
5.51

11.397
4.88
0.99

1.084
0.67
0.95

-0.77
0.71
1.01

4.38
2.05
4.25

11.4
5.2
5.5

3.12
2
2.06

Average Δ

0.75

0.55

2.93

3.50

5.76

0.90

0.32

3.56

7.37

2.39

10X FFF, 2 Partial
Fields RapidArc ,
30/330 Collimator

< 1000cc < 1500cc
Max
SpinalCord <
SpinalCord
receives receives
Lung V20 (Gy) V5 (Gy) 0.25cc receives > <0.5cc receives
> 13.5Gy > 12.5Gy
(%)
22.5 Gy (Gy)
> 13.5 (Gy)
(Gy)
(Gy)

PTV Volume
(cc)

PTV 2cc
(Gy)

16.4
9.6
10.2

57.43
55.89
57.71

Table 6: Dose Volume Histogram for Photon Plans

Figure 0-2: Dose Colorwash and motion distribution of Free vs. HFPV plans
1.25.10
iscussion

D
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It is apparent from previous studies and trials like SABR-COMET and
RTOG 0617 that reducing margins is critical in sparing organs at risk which
consequently result in fewer side effects.
In this simulated retrospective phantom study, we evaluated whether
motion reduction by HFPV is dosimetrically beneficial. We assumed that chest
wall motion acquired from the volunteers undergoing free- and HFPV- breathing
was the same as tumor motion. It was elected to use the smaller slice thickness
due to the small size of the target. The 95 % normalization was used as a
baseline for comparison. Motion of the rod was >10 mm for free breathing and
<5 mm for HFPV-breathing.
As the results indicate, the volume of the PTV was drastically reduced
from free to HFPV breathing. The expansion margin from ITV to PTV was kept
at 5 mm for all plan. In one of the scans, the lung volume was < 1500 cc,
therefore no data was reported. V5 and V20 of the lung experienced the
greatest dosimetric benefits from HFPV by reducing the dose by > 5Gy and >3
Gy, respectively.
1.25.11

C

onclusions
HFPV can drastically improve the dosimetric parameters for SBRT plans when
compared to free-breathing. V20 improved from 5.44Gy to 1.94Gy and V5 from
16.49Gy to 10.75Gy.
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CHAPTER 7: NEW MASK DESIGN AND REPRODUCIBILITY
1.26 Mask Design
Upon review of the subjective scores, analysis of data from Anzai system
and SenTec monitoring system from all 15 volunteers enrolled in Cohort I, we
concluded that to optimize the comfort of HFPV for patients undergoing
radiotherapy a custom mask is important. In the new designed mask, we aimed
at resolving some of the shortcomings that the commercial masks exhibited
during Cohort I.
1.26.1 Commercial Design Shortcomings
Fischer & Paykel Oracle 452 interface resulted in the longest times under
HFPV. However, air leakage through the side of the patient’s mouth resulted in
loss of percussive bursts and drift in amplitude. Although, it had a strap around
the mask, volunteers indicated it was difficult to hold in place with their teeth.
Additionally, it introduced the highest dry throat and the nasal prongs continually
fell off. The above issues make this interface less optimal for radiotherapy.
Amici Tru-Fit was the most difficult to hold in place due to lack of straps.
Therefore, it was held in place by hand. Similarly, to the above device, the nasal
prongs continually fell off. CO2 level increased faster with Amici Tru-Fit than the
other two devices. Holding this device by hand would not be optimal for patients
undergoing radiotherapy due to gantry rotation around the patient and other
inconsistent placements.
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Phillips Respironics Oro-Nasal mask was the most comfortable based on
the subjective scores. All volunteers indicated that it rested comfortably on their
face, however they did not feel well ventilated. It was noted that the high
frequency bursts would “puff up” the patients’ cheeks, resulting in the delivery of
pressurized pulses within the buccal space and oral cavity rather than their
oropharynx. Delivery of pulses in buccal space and low duty cycle for this
interface would create inconsistent results in target immobilization
During clinical radiotherapy treatments, patients are accompanied into
the radiotherapy treatment room by the Radiotherapy Technician (RTT). The
radiotherapy room is a large vault that is shielded by several feet of concrete on
all sides; in addition to the multi thousand-pound steel door that provides
protection to the outside staff while the linac is on. After the patient is setup on
the treatment couch, the therapists will exit the vault. Once outside, they will
take preliminary imaging to verify isocenter and then deliver the treatment. The
patient is in the treatment room by themselves (audio and visual is mandatory).
As a result, our current three masks and Phasitron tubing have major limitations
in radiotherapy. To address them we proposed:


Design a custom mask with a valve that would allow the patients to
switch between the ventilator and room air.



Design custom nasal prongs that are either part of the mask or don’t fall
off during radiotherapy treatment (usually 15 to 30 minutes).

110


Design a custom mask that would allow the delivery of the pressure wave
pulses to the oropharynx, beyond the buccal space and oral cavity while
maintain mandible comfort.

Additionally, during our Cohort I measurements, the volunteers were setup in
a research room where the Oxygen supply, Phasitron and Phasitron tubing was
within three to five feet from the patient. Therefore, long tubing to connect the
patient to the high frequency air bursts was not necessary. Such setup would
not be possible in a clinical radiotherapy room since the patient is in a room by
him or herself. The Percussionaire (IPV Control System) will be positioned
outside of the room to protect the technician operating it from high doses of
radiation while the patient receives treatment. To overcome such matter, we
propose:


Custom design of longer tubing that would allow for the same mechanical
impedance.



Development and Design Partners

1.26.2 Beaumont HFPV Mask Design
1.26.2.1
ntroduction

I

To improve the shortcomings from the commercial masks, a new HFPV
mask was designed and prototyped to accommodate for: 1) air leakage around
the mouth, 2) direct delivery of the bursts into patients’ oropharynx (less puffy
cheeks), 3) patients’ ability to control between room air and HFPV, 4) longer
Phasitron tubing for MRI imaging.
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1.26.2.2
ethods

M

Beaumont HFPV design and prototype, with some commercially
available components, are shown in Figure 0-1 through Figure 0-2. We
recruited five volunteers to undergo four HFPV sessions with the new prototype.
They were positioned flat on the treatment table with their arms above their
head. Their chest-wall motion was monitored using the Anzai system. A total of
20 free- and 20 HFPV-breathing patterns were analyzed. For each breathing
pattern we calculated the absolute difference between the max (peak) to min to
min (peak) value. The % reduction in motion for HFPV was relative to the free
breathing for each individual session.
1.26.2.3
esults

R

Figure 0-1 is an overview of the initial design. The straps would allow the
mask to fit tightly around the patient, while the mouthpiece with the adjustable
length allows for additional fine tuning of the interface. The ability to adjust the
mouthpiece would allow the bursts of air to be delivered directly into the
patients’ oropharynx without creating “puffy cheeks”.
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Figure 0-1: Overview of Beaumont Mask Design with some AF451
Commercially available integration-ECRLab Design
Figure 0-2 shows how each component fits together whereas Figure 0-3
shows the positioning and design of the diverter valve that would allow the
patient to switch between room air and HFPV. The placement of the diverter
valve was investigated (Figure 0-5). We decided to place it as close to the
Phasitron as possible to eliminate introducing dead space between the
Phasitron and diverter (recommended < 50 mL), which would consequently
introduce drop in pressure and discomfort to the patient.

113

Figure 0-2: Components of the mask: Commercially available AF451 integrated
with a fabricated 3D printed adjustable mouthpiece-ECRLabs Design
A diverter valve that slides in and out was designed to allow the patient to

Figure 0-3: Diverter Valve placement
switch between room air and HFPV in the event of an emergency. This design
allows for the HFPV bursts to be escaping outside of the patient if it is in the ON
position and back into the patient if it is in the OFF.
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Figure 0-4: Close-up of the mouthpiece assembly
Several options were also investigated and tested on volunteers in and effort to
further revising the prototype. One such option is shown in Figure 0-5 E. A new
mouthpiece was introduced to investigate comfort around the patient for future
prototyping.

A

B

C

D

E

F
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Figure 0-5: The prototype of the mask is shown in A, B, C, E and F. A and B
shows a good fit on the volunteer. C shows diverter placement away from the
Phasitron. D is the custom tubing (15 and 20 feet), E) shows a slight modification
of the mouthpiece for further testing
All volunteers recruited for this study, successfully completed each
HFPV session using the setup demonstrated in Figure 0-5B. A total of 20 freeand HFPV- sessions were analyzed. The mean peak-to-peak chest wall motion
for free breathing was 12.91 cm (SD: 4.15) and the mean peak to peak for
HFPV breathing was 2.88 cm (SD: 1.33).
1.26.2.4
iscussion

D

Data acquired with the first Beaumont HFPV mask provided promising
results. HFPV peak-to-peak motion improved compared to the commercial
Fischer Paykal, 2.88 cm (SD: 1.33) vs. 3.8 cm (SD: 0.96). We believe the
improvement was due to the adjustable mouthpiece (Figure 0-4) which allowed
the bursts of oxygen to be delivered directly to the oropharynx as opposed to the
buccal space. We also noticed that all volunteers experienced less “puffy
cheeks” which is a subjective validation that the percussions were being
delivered into the oropharynx
The silicone 3D printed oral part of the mask (depicted as the portion
closest to the headgear in Figure 0-2), was not as comfortable as the
commercially available devices. The volunteers indicated that lack of prongs for
teeth to rest on (like the Amici Trufit) is essential. Additionally, with the new
diverter valve and adjustable components, the assembly became heavy and
harder to hold by hand for long periods of time. Therefore, for this initial version
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of the prototype, we did not investigate the amount of time at which each
volunteer could be under HFPV. Further improvements to our initial prototype
will be made to account for teeth resting prongs, like that depicted in Figure
0-5E, as well as providing support for the entire assembly to be hands free. All
volunteers felt well ventilated and minor changes in CO2 levels were noted.
The diverter valve was functioning as designed, however some force was
required to slide it ON and OFF. We aim to further improve the initial prototype
to accommodate for patients with minimal strength.
1.26.2.5
onclusions

C

Our initial prototype provided great improvements to the air delivery into
the oropharynx. Our second version of the prototype will be adjusted to
accommodate for teeth resting prongs, to prolong patient comfort, as well as
providing support for the entire assembly to stay fixed on the patient.
1.27 Reproducibility of HFPV
1.27.1 Abstract
Purpose: The purpose of this study is to identify the chest-wall reproducibility of
HFPV as a method for mitigation thoracic motion.
Methods: Five volunteers underwent HFPV in three different days. Each day,
they underwent five separate sessions and each session entailed of two 1minute long HFPV sessions with free breathing in between. Chest wall motion
was monitored using the Anzai (Anzai Medical Co., Tokyo, Japan) laser system
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which was projected 10 cm inferior to the xyphoid process. Intra-session
reproducibility was calculated by obtaining the difference (Δ) between 2 HFPV
sub-session means for each the 5 sessions. Inter-session reproducibility was
calculated by taking the maximum-minimum difference of the mean daily (Δ).
Results:
A total of 75 sessions were analyzed for all 5 volunteers. Intra- session
reproducibility for HFPV was calculated at 1.50 mm (SD: 0.82 and 1.56 mm (SD:
0.56) for free breathing. Inter-session reproducibility was 1.10 mm (SD: 1.27)
and 0.80 mm (SD: 0.6) for free- and HFPV- breathing, respectively.

Conclusions:

HFPV

can

be

a

reproducible

technique

for

thoracic

immobilization to within 2 mm, however initial lung volume at on-set of HFPV
plays an important role in consistency.
1.27.2 Introduction
Due to biological effectiveness, in almost all thoracic radiotherapy tumors,
the dose is delivered in multiple fractions which entails each patient being
imaged and treated daily. The fractionation varies between 3 to 5 for SBRT and
as high as 30 or more for conventional radiotherapy. Each patient is setup daily
on the treatment couch, by the radiological technologist, the same way they
were setup during their initial CT-Sim, which is the CT that the computerized
treatment plan was designed from.
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Because of the daily setups or even multiple setups in one day, it is
critical that HFPV inter- and intra- fraction reproducibility is quantified. This
would allow clinicians to have confidence (and comfort to the patient) that, if the
treatment should be halted for any reason, applying the same parameters
(pressure, frequency etc.) as those set in the CT sim would bring the patient to
the same initial setup. Similarly, applying the same initial parameters daily
should produce the same results. Although, in slightly different circumstances,
data has shown that lung function can change over time, therefore it is possible
that over a 6-week (Magnussen, et al., 2016) radiotherapy course, patients’
ability to tolerate the same pressure and frequency may change. In that event, a
new HFPV baseline can be set followed by imaging and other departmental
protocols.
Additionally, during Cohort II study, we noticed a slight baseline drift,
which we attributed to the increase in CO2 of the patient which triggered them to
gradually stop HFPV. In this study we aim to evaluate intra- and inter fraction
reproducibility as well our ability to adjust the baseline shift by altering the dials
on the Percussionaire IPV-2C unit.
1.27.3 Methods
We recruited 5 healthy volunteers to undergo HFPV with the Beaumont
designed prototype. Each volunteer underwent five sessions (Ns=5) of
percussive ventilation in three sperate days (Nd=3). Each session (Ns) consisted
of two individual sub-sessions of HFPV (Nss=2) of 1 minute long with re-
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breathing in between (Figure 0-6). A total of Ns=75 sessions and Nss=150 subsessions were acquired for all volunteers Figure 0-7 in three different days.
Volunteers were positioned on a flat table with the Anzai laser system
projected approximately 10 cm inferior to the xiphoid process. Like Cohort I,
their CO2 was monitored using the Sentec monitoring system. Each volunteer
underwent an initial training session of approximately 30 minutes prior to the
initiation of the study. The baseline parameters of the Percussionaire (pressure,
frequency, cpap and inspiration time) were also set during the initial training
session.
The data acquired from the sessions in the first day followed right after
the initial training session, therefore the baseline parameters were used. During
the consecutive days, the volunteers were set with the same parameters as the
previous day, but minor adjustments were made if the volunteer felt
uncomfortable from lack of pressure, frequency etc. The Percussionaire settings
were kept unchanged within each daily session.
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Figure 0-6: Reproducibility study methods

Figure 0-7: Definition of Session, Sub-Session. Each volunteer underwent 5
sessions a day for three days and each session consisted of 2 sub-sessions
with free breathing in between.
Intra-session reproducibility was calculated for all of the Ns=75 sessions. For
each of the sessions, the mean location (Y-Axis (mm)) of the sub-sessions
(indicated by red and green in Figure 0-8) was calculated and the absolute Δ
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difference (mm) was calculated. The same methodology was also followed for
free breathing.

Figure 0-8: Method of calculating reproducibility
Inter-session reproducibility was calculated by taking the maximum to
minimum difference in mean delta for all three days. Additionally, the percent
change in pressure, cpap, frequency and inspiration time were recorded for
each day.
1.27.4 Results
All volunteers that were recruited successfully completed all three days of
HFPV. All reached a total peak volume of approximately 18-20 cmH2O and
frequency between 300-350 bursts/min.
1.27.4.1
ntra-Session Reproducibility

I

Intra- session reproducibility for free breathing was calculated to be 1.56
mm (SD: 0.56). The results are represented in Table 7.
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Day 1

Day 2

Day 3

Free Breathing Intra-Session Reproducibility (mm)
V#1
V#2
V#3
V#4
V#5
Session 1
2.39
2.02
1.30
1.77
0.27
Session 2
1.49
0.02
1.00
1.34
2.54
Session 3
2.41
2.84
2.66
0.01
0.61
Session 4
0.04
1.37
0.64
2.45
0.42
Session 5
3.69
1.66
0.23
0.51
2.25
Session 1
1.51
0.32
1.06
4.96
0.18
Session 2
3.00
1.54
0.78
1.98
0.70
Session 3
0.08
0.64
0.91
4.16
1.48
Session 4
1.07
0.67
2.63
4.86
1.08
Session 5
2.16
1.33
0.02
6.48
0.71
Session 1
1.73
1.72
1.16
0.64
0.61
Session 2
1.56
1.33
2.26
0.80
0.27
Session 3
1.97
2.13
0.86
2.79
2.12
Session 4
1.48
2.17
1.28
2.31
0.57
Session 5
2.61
3.01
0.67
0.17
0.15
Average (mm)
1.81
1.52
1.16
2.35
0.93
SD (mm)
0.98
0.86
0.79
1.96
0.79
Total Average
(mm)

1.56

Total SD
(mm)

0.56

Table 7: Free breathing intra-session reproducibility
Intra- session reproducibility for HFPV breathing was calculated to be 1.50 mm
(SD: 0.82). The results are represented in Table 8.
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Day 1

Day 2

Day 3

HFPV Intra-Session Reproducibility (mm)
V#1
V#2
V#3
V#4
Session 1
1.35
4.87
1.17
2.99
Session 2
1.23
0.30
1.10
0.77
Session 3
2.38
3.27
0.96
1.86
Session 4
0.64
0.01
1.44
0.22
Session 5
3.35
0.18
0.40
0.18
Session 1
0.59
2.89
2.36
1.12
Session 2
4.05
7.53
0.63
2.15
Session 3
2.30
1.55
0.65
0.78
Session 4
0.49
4.76
1.99
3.00
Session 5
4.24
0.69
0.86
1.79
Session 1
4.55
2.15
2.11
1.75
Session 2
1.81
6.05
0.58
0.16
Session 3
2.71
2.33
1.87
0.46
Session 4
1.64
0.22
0.94
0.06
Session 5
1.09
0.10
0.95
1.41
Average (mm)
2.16
2.46
1.20
1.25
SD (mm)
1.36
2.41
0.61
0.99
Total Average
(mm)

1.50

Total SD
(mm)

V#5
0.42
0.13
0.17
0.28
0.09
0.56
0.30
0.10
1.36
0.68
0.16
0.63
0.09
0.43
1.04
0.43
0.38

0.82

Table 8: HFPV intra-session reproducibility
1.27.4.2
nter-Session Reproducibility
For free breathing inter-session reproducibility was 1.10 mm (SD: 1.27)

I
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V#1
V#2
V#3
V#4
V#5

Free Breathing Inter-Session Reproducibility
Day 1
Day 2
Day 3 Largest Delta (mm)
2.00
1.57
1.87
0.44
1.58
0.90
2.07
1.17
1.17
1.08
1.25
0.17
1.21
4.49
1.34
3.27
1.22
0.83
0.74
0.47
Average
1.10
(mm)
SD (mm)
1.27

Table 9: Free-breathing inter-session reproducibility
For HFPV breathing inter-session reproducibility was 0.80 mm (SD: 0.6)

V#1
V#2
V#3
V#4
V#5

HFPV Breathing Inter-Session Reproducibility
Day 1
Day 2
Day 3 Largest Delta (mm)
1.79
2.33
2.36
0.57
1.73
3.48
2.17
1.76
1.02
1.30
1.29
0.28
1.21
1.77
0.77
1.00
0.22
0.60
0.47
0.38
Average
0.80
(mm)
SD (mm)
0.60

Table 10: HFPV-breathing inter-session reproducibility
On average the changes made to the settings of the Percussionaire
device from day-to-day for all volunteers were 3.27, 0.36, 6.91, and 0.73% for
inspiration time, frequency, pressure and CPAP, respectivally (Table 11).
Range of change for each dial varies between increments of 1 (0%) to 12
(100%).
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Average Change(%)
A Insp Time
3.27
B Frequency
0.36
C Flow Pressure
6.91
D CPAP
0.73
*1 incremental dial introduces ~ 9% change

Table 11: Daily adjustments of the Percussionaire parameters
1.27.5 Discussion
The aim of this study was to calculate our ability to reproduce position. All
measurements were calculated based on chest wall motion, therefore
reproducibility of the tumor may or may not be the same as that of the chestwall.
The total average intra- session reproducibility for free breathing was
1.56 mm +/- 0.56 mm and for HFPV 1.50 mm +/- 0.82 mm. Although, these
results are promising in our abilities to position the patient at the desired location
in the event that the treatment was interrupted, the main factor that can alter the
results is the amount of initial volume of air that the patient inhales at onset of
HFPV. It was noted that HFPV maintained consistent volume delivery, however
taking the voluntary mid- or full- inhale breath at onset of HFPV allowed for the
slight variations in chest-wall positioning. Therefore, it is recommended that the
patients are provided with adequate HFPV training (approximately 1 hour) to
establish good familiarity with the device as well as their ability to take the
consistent initial volume at onset of HFPV.
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The total maximum inter-session variability was calculated to be 1.10 mm
+/- 1.27 mm for free breathing and 0.80 mm =+/- 0.6 mm for HFPV breathing.
Recalling that although each day the volunteer was setup with the same
percussionare settings as the day prior, slight adjustments were made per
volunteer’s request. These adjustments were on an average +/-1 increment
(Table 11) where each increment introduced >10 % change. Therefore, we
believe that patients can be consistently setup from day to day, but minor
adjustments of the pressure, cpap, inspiration time and frequency maybe
needed (+/- 5%).
Consistency in free-breathing was simply calculated for comparison. It
was noted that almost all volunteers increased their inhale air volume for the first
10 seconds after HFPV was turned off (deeper free-breathing). We attribute this
to our natural receptors and probably CO2 level increase (Section 1.28).
Additionally, chest-wall position for some volunteers experienced and spike of
about 6 to 10 seconds before leveling off. We believe that this is due to the CO2
levels (Section 7.4).
Volunteers noted that the weight of the new Beaumont prototype would
cause the mouthpiece to move, therefore causing loss of pressing. Further
fixation changes will be made to the prototype to ensure stability of the device
on the patient while prolonging their comfort and percussions. Therefore, this
study only looked at the reproducibility of HFPV sessions with the 1-minute
window. Therefore, reproducibility for longer than 1-minute intervals maybe
different.
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1.27.6 Conclusions
The reproducibility of HFPV is <2 mm, however it could vary depending
on the initial lung volume at onset of HFPV. Up to +/- 10 % adjustments for
some of the Percussionaire parameters maybe needed daily.
1.28 CO2 and Amplitude Drifts during HFPV
During initial measurements it was noted that, at onset of HFPV, chest-wall
motion experienced an initial peak before it leveled off approximately 6 to 10
seconds later Figure 0-9. Additionally, the consistency and peak-to-peak motion
of HFPV began to deteriorate after a few minutes under HFPV (> 3 to 5
minutes). This was further investigated and concluded that CO2 levels play a
direct role in baseline drift.

Figure 0-9: First arrow indicates the initial peak of chest-wall motion during
onset of HFPV and the second arrow represents the increase in CO2
The CO2 levels were recorded throughout the HFPV session and it was
noted that at onset of HFPV the CO2 level begins to drop due to the initial
continuous positive air pressure Figure 0-10. This decrease in CO2 directly
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correlates with the initial chest-wall motion of HFPV that was noted on most
volunteers. There is a leveling off window of the CO2 which is an indication of
good ratio of O2 to CO2 exchange in the patient, therefore having a specifically
designed oral mask that would provide equal exchange is critical in maintaining
reproducibility and consistency.

Figure 0-10: CO2 level during HFPV
Similarly, as the CO2 level increased the HFPV became less consistent.
This data is overlaid with the HFPV curve of the same patient/time in Figure
0-11. It is evident that as CO2 decreases at onset of HFPV the chest wall motion
experiences an initial decrease. While the CO2 is maintained constant, the
HFPV is consistent and therefore desirable. Subsequently, as CO2 beings to
increase, HFPV becomes less consistent which results in patient’s desire to
terminate the session.
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Figure 0-11: Correlation of CO2 and HFPV Chest wall Motion
Furthermore, we investigated whether CO2 is linearly correlated to peakto-peak amplitude drift of HFPV. The upward drift of CO2 in the top right section
of graph in Figure 0-11 had a slope of 3.9 mm (Max – Min), for the same
corresponding HFPV curve the downward drift had a slope of 4.2 mm. These
results were further tested with a balloon experiment.
1.28.1 Methods
A plastic balloon was inflated to maximum capacity and the Anzai laser
system was projected as in all prospective studies (Figure 0-12). In the first
experiment, inspiration time, CPAP and pressure dial were kept constant while
the frequency was incrementally changed from the highest dial (1) to the lowest
(12), while simultaneously acquiring motion amplitude of the balloon with the
Anzai system.
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For the second experiment, the inspiration time, CPAP, and frequency
dial were kept constant, while pressure dial was incrementally changed from the
highest (1) to lowest (12).
Lastly, for the third experiment, inspiration time and CPAP dial were kept
constant while simultaneously changing both the flow and the frequency. The
pressure increased incrementally from the lowest (12) to the highest (1) dial,
while the frequency decreased by the same amount.

Figure 0-12: Setup of the Balloon measurements
The manual dial of 12 (~8 %) indicated the lowest and 1 (100 %)
indicated the highest. The mean distance from the laser to the balloon was used
for each change in frequency, pressure or both.
1.28.2 Results
Each increment on the frequency dial, from 3 to 9, resulted in a slope of
0.4 mm (Figure 0-13), indicating that every incremental dial on the frequency
knob may introduce an upward or downward (depending on direction) drift of
about 0.4 mm for each turn.
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Figure 0-13: Incremental Change in Frequency. Frequency went from highest
(1) dial to lowest (12).
Similarly, incremental changes on the pressure dial between the range of
3 to 9, resulted in an average slope decrease of 1.21 mm (Figure 0-14).
Indicating that decreasing the pressure dial by one increment would
subsequently decrease the baseline drift slope by 1.21 mm.
Changing both frequency and pressure resulted in a slope of 0.3 mm
(Figure 0-15). A composite of all data is given in Figure 0-16.
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Figure 0-14: Incremental Change in Pressure. Pressure went from highest (1)
dial to lowest (12).

Figure 0-15: Incremental both Pressure and Frequency. Frequency went from
highest (1) dial to lowest (12) and Pressure in the opposite direction
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Figure 0-16: Composite data
1.28.3 Discussion
It is evident from the results that the initial decrease in CO2 level plays an
important role in the initial spike at onset of HFPV. As a result, if HFPV is used
for imaging or radiotherapy, it is important to do so 6 to 10 seconds post HFPV
initiation. It would allow for the CO2 to O2 ratio to become constant.
Change in frequency behaved in a linear fashion with an R^2 value of
0.9317, but the average slope between each dial was higher for the pressure
knob. Indicating that changing the pressure has a higher effect on the ability of
the lungs to stay inflated than the frequency. However, the high frequency rate
is necessary to maintain the appropriate CO2 and O2 gas exchange. Therefore,
results in Figure 0-15 are promising. Likewise, changes in pressure behaved
linearly between the dials of 3 and 9 with an R^2 value of 0.9192 and slope of
1.18 mm.
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Adjustments between pressure and frequency made in the third
experiment, resulted in a slope of 0.3 mm, however it maybe the desired method
as it would allow the user to slowly adjust for amplitude drifts while maintaining
good pressure and frequency without introducing discomfort to the patient.
In Section 1.27, the mean intra- and inter- fraction reproducibility was
1.50 mm (SD: 0.82) and 0.80 mm (SD: 0.6), respectively which is within the
range of our ability to adjust the pressure and frequency dial while the patient is
in HFPV, which would correct for any amplitude drifts or CO2 increase. These
changes would allow the clinicians to comfortably keep the patient in HFPV for
the entire duration of their treatment.
Lastly, it is critical that a balance between pressure and frequency is
maintained during HFPV. The pressure would allow for the lungs to stay inflated
while the frequency allows for good exchange of CO2 to O2. Ideally the rate of
exchange should be

= 1, an indication that the oxygen bursts are

entering the lungs just as fast as CO2 is leaving. If the

ratio is >1 the CO2

will continue to rise, triggering the patient to stop HFPV. Conversely a
ratio of <1 can result in alkalosis.

1.28.4 Conclusions
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Maintaining a unity ratio of CO2/ O2 is critical in prolonging HFPV times as
well as reproducibility. Incremental changes in the frequency and pressure dial
of the Percussionaire could allow for adjustments in amplitude drifts during
treatment or daily positioning.
CHAPTER 8: CONCLUSIONS OF DISSERTATION
1.29 Hypothesis Restatement
It was hypothesized that HFPV:
1. HFPV provides direct tumor immobilization of <5 mm for all targets
exhibiting respiratory motion >10 mm
2. HFPV reproducible thoracic immobilization with <5 mm residual motion,
over 1-minutes intervals with rebreathing between each instance.
3. Significantly reduces the interplay effects noticed in pencil beam
scanning proton radiotherapy.
4. HFPV can significantly reduce the PTV margin for thoracic targets and
subsequently healthy tissue toxicity
1.30 Set Aims
1.30.1 Set Aim I
The primary objective of this study is to test if HFPV can be a viable method for
thoracic immobilization
1.30.2 Set Aim II
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A second primary objective is to evaluate if HFPV can reduce lung tumor motion
from ≥ 10 mm to < 5 mm. This will be the first study to directly measure tumor
motion reduction using HFPV.
1.30.3 Set Aim III
A second objective is to evaluate the reproducibility of HFPV immobilization. Will
the target return to the same location after re-breathing then repeat HFPV?
1.30.4 Set Aim IV
Another secondary objective is to evaluate the interplay effects of HFPV motion.
1.31 Hypothesis Response
1. In Chapter 1.24 we were the first to directly measure tumor motion with
HFPV. Despite patients’ history of COPD and a peak pressure less than
desired (12cmH2O vs 20cmH2O), tumor motion was reduced from 10
mm in 4DCT to 2.67 mm
2. This is the first study to directly measure reproducibility of HFPV as a
technique for thoracic immobilization. In Chapter 1.27.4 mean intrafraction reproducibly (Nss=75) was calculated at 1.50 mm (SD: 0.82) and
inter-fraction at 0.80 mm (SD: 0.6).
3. The interplay effects for proton PBS were significantly reduced. In
Chapter 1.21.1 it was concluded that Gamma passing rate, with 3%/3mm
and 10% threshold criteria, improved from 77.03 % during free-breathing
to 99.20 % during HFPV breathing. Similarly, hot and cold spots were
drastically reduced from 10-30% to 5-10% during HFPV.
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4. In Chapter 1.25.9 it was concluded that although the margin applied from
ITV to PTV was kept at 5 mm, the PTV volume was drastically reduced
during HFPV. In free-breathing PTV volume was 12.037 cc vs. 4.7 cc for
HFPV. Similarly, V20 and V5 of the lung was drastically reduced from a
mean of 5.44 Gy (Range: 3.3 -7.97Gy) to 1.94 Gy (Range: 1.68 – 2.46
Gy) for V20 and 16.49 Gy (Range: 14.3 – 20.24 Gy) to 10.74 Gy (Range:
8.84 – 13.31 Gy), for V5 for Free vs. HFPV breathing respectively.
1.32 Long Term Goal and Future Work
Future use of HFPV will entail multiple aspects of radiotherapy as indicated in
Figure 0-1.

Figure 0-1: Long term goals of HFPV

1.32.1 Imaging:
Further work will be performed in determining the benefits of HFPV for
reducing motion artifacts in a multi-modality setting like MR, CT and PET. Prior
work by (Beigelman-Aubry, et al., 2017) reported a drastic increase in spatial
resolution of chest MRI for volunteers undergoing pulsatile flow, similarly (Prior
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J. a., 2016) reported an increase in legion SUV for patients undergoing pulsatile
flow. Utilizing HFPV for all image modalities in radiotherapy is feasible and
further work will be performed to validate them. An MRI protocol with HFPV has
already been written and submitted to the IRB for approval.
1.32.2 Planning:
We have shown that HFPV can drastically reduce dose to the OARs while still
maintaining high target dose. Our future directions include application of HFPV
to proton radiotherapy as well as heart ventricular tachycardia. A recent
publication (Cuculich, et al., 2017) validates the importance of radiotherapy for
ventricular tachycardia, however no respiratory motion was used in the study.
Therefore, future work entails using HFPV for ventricular tachycardia due to its
prolonged time as well as reproducibility.
1.32.3 Treatment:
In this study we have shown great benefits of using HFPV in PBS, photon and
MR setting. Our future direction entails the use of HFPV for treating lung cancer
with MR-Linac as well as conventional photon or proton accelerators.
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This work investigates the use of High Frequency Percussive Ventilation as
a technique for respiratory motion mitigation in radiotherapy. This technique was
extensively investigated in several prospective and retrospective studies.
In an initial prospective study, we evaluated the feasibility of HFPV and
chest-wall motion reduction, by recruiting 15 healthy volunteers to undergo
HFPV with three commercially available interfaces. For direct tumor motion
immobilization, a second prospective study was performed in which with ten
lung cancer patients underwent HFPV while imaged with high frame rate
fluoroscopy. Diaphragm motion and image artifacts were quantified in a
prospective study of a healthy volunteer that underwent MRI while undergoing
HFPV. Several retrospective studies were performed to quantify the interplay
effects as well as gradient effects of HFPV vs. free breathing in photon and
proton radiotherapy. Furthermore, a retrospective phantom study was performed
for quantifying PTV volume reduction as well as doses to the organs at risk.
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Reproducibility of the HFPV was evaluated in a prospective study of five
volunteers who underwent five sessions of HFPV in three different days. Lastly,
as part of this study, a HFPV mask was designed and prototyped for better
comfort, prolonged percussive time, minimal baseline drifting, as well as patientcontrolled valve.
HFPV provides prolonged breath-hold like apnea in awake patients that
could last as long as 16 minutes. In this first ever study, direct tumor motion was
drastically reduced from > 10 mm to < 3mm. Similarly, diaphragm motion was
reduced by as much as > 90 %.

HFPV proved significantly beneficial in

reducing effects of interplay in proton radiotherapy and photon dose gradient
measurements, increasing gamma index by as much as 20 to 30 % from free
breathing to HFPV. Similarly, hot and cold spots were reduced by > 50 %. HFPV
is reproducible within < 2 mm both intra- and inter- fraction, but it can be further
improved by applying minor adjustments to the pressure and frequency of the
Percussionaire unit.

Although further modifications will be made, the newly

designed prototype provided less leakage and better comfort as well as
providing patients with the direct ability to switch between room air and HFPV.
HFPV is novel and promising technique for tumor immobilization in a
radiotherapy setting.
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